Prosthesis for supporting a breast structure

Description

BACKGROUND
1. Technical Field

The present invention relates to a prosthesis for supporting a breast structure, such as a breast implant or breast tissue within a patient.

2. Background of Related Art

Breast cancer is one of the most common cancers among women. If the disease is not caught early, it is common that large portions of breast tissue are removed. In a conventional procedure called mastectomy, one or both breasts are partially or completely removed in order to treat or subsequently prevent breast cancer. Since such procedures generally result in a substantial amount of tissue being removed, many women will then opt for breast reconstructive surgery in order to reform the breast into a natural looking state. It is often acknowledged that the process of cancer treatment and removal of breast tissue can weigh heavily not only on the patients physical but also emotional well being. Thus, such surgery to reconstruct the breast can allow the patient to maintain self confidence after such an ordeal.

With reference to FIG. 1 is shown a healthy breast 1. The breast 1 is formed of fat tissue 3 encompassing lobules 4 and milk ducts 5 converging towards the nipple-areola complex 2. With reference to FIG. 1, are further shown the infra-mammary fold 6 which defines the lower end of the breast 1, the pectoral muscle 7, the chest wall 8 formed of the ribs 9 and of the intercostal muscles 10, and eventually the skin 11.

Within the framework of a mastectomy, lobules 4 and milk ducts 5 are removed from the breast 1.

SUMMARY

Many techniques of breast reconstruction are known in the art. Such procedures generally involve employment of implants, one's own body tissue, or a combination thereof, which are employed for reforming the breast. Implants are the most common technique known in the art and are used for reconstructive surgery. This involves the employment of silicon, saline, or other suitable material formed implants which may be placed under the pectoral muscle (submuscular) for forming and shaping the breast.

With reference to FIG. 2, is shown a reconstructed breast 1, in which the lobules and milk ducts have been removed and replaced by a breast implant 12 which is placed under the pectoral muscle 7. As shown on this figure, the breast implant 12 has the global shape of a water drop with a curve-shaped lower portion and a substantially conical upper portion.

Because of the weakening of the biological tissues around the breast implant due to mastectomy, it may happen that after some time, the breast implant bottoms out, in other words moves downwards under the effect of natural gravity. Such a phenomenon often requires surgery in order to either remove the implant or reposition it correctly. For these reasons, implant-based breast reconstruction is usually used in combination with an implantable material intended to provide a layer of long-term support for the breast implant, for enhanced and shape of the breast, such implantable material generally having the shape of a sling and acting as an internal bra.

Moreover, independently from medical reasons such as breast cancer, many women may decide to undergo breast surgery on a healthy breast in order to lift up the breast for purely aesthetic reasons. In such a case, no part of the biological breast tissue is removed, and a material such as a tape or a sling is implanted underneath the breast in order to lift it up and to support it.

The use of medical surgical mesh material as a support member for a breast structure is known in the art. In the present application, by «breast structure» is meant both a breast implant, replacing the removed biological breast tissue in case of reconstruction of a breast after a breast cancer, or the natural biological breast tissue, in case of purely aesthetic surgery. Conventionally, the surgical mesh is provided as a flat substantially rectangular or square sheet that the physician must accurately cut to size in an attempt to fit the natural curvature of a breast and to provide adequate support for the breast structure.

These square or rectangular sheets of mesh fabric are neither configured to size nor cut to shape to form the proper three dimensional shape when placed in a supportive engagement in an arc under the breast implant. Surgeons must take valuable time and cut the fabric sheet in the operating room during the procedure. In particular, the surgeon must cut the mesh and use trial by error in order to achieve the best form-fitting shape. This is time-consuming and fastidious for the surgeon, and unconfortable for the patient. This need for cutting mesh fabric may result in uneven or miss-cut sheets of mesh which are then implanted and must be forcefully stretched or manipulated into a “fitted” engagement to the breast of the patient. To maintain this fitted engagement, the surgeon resorts to sutures through the mesh and into surrounding tissue. It may also happen that the surgeon has to fold parts of the mesh on itself, thereby creating additional thickness resulting in an improper fit around the curved area of the breast tissue or implant and possible painful feeling for the patient. Folds may also cause unnatural appearance.

In addition, the dimensions and configurations of the mesh for each breast will vary widely for each instance of the procedure and the desired outcome of breast size, shape, and form. The lack of customized supporting prosthesis for breast implants can adversely effect the finished shape and feel of the reconstructed breast tissue. Patients may suffer from discomfort from the material compressing the breast tissue or implant, or from a distaste for the visual aspects of the finished surgery. Patients may require further surgeries to correct any inconsistencies with the mesh, or may just unfortunately live with the uncomfortable current state of the reconstruction.

Moreover, the conventional synthetic mesh materials used today make no provision for accommodating stretch in one or both directions on a controlled basis. Known devices may therefore fail in providing adequate support and comfort in the natural movement and feel of the breast which for each human is of a custom dimension and area. This poor fit and lack of elasticity may result in additional surgeries to correct such inconsistencies.

The stiffness of surgical mesh conventionally employed with breast reconstructive surgery can seriously inhibit the natural look, movement, and feel of the breast tissue and such is undesirable. Further, stiff materials formed into meshes can prove more difficult to handle by the physician during implantation due to the need to customize the planar sheet, to fit the curved three dimensional shape of a breast. Such misfitting sheets customized in the operating room may require additional suturing to maintain their position in the body.

There is therefore a need for a prosthesis capable of supporting a breast structure, such as a breast implant post mastectomy or the biological breast tissue in an aesthetic surgery, said breast structure being a non planar body having three-dimensional curves, in a manner that would be the closest as possible to the natural biological support, regarding on one hand strength of the support in order to avoid sagging of the supported breast structure, and on the other hand elasticity of such support in order to provide a comfortable feeling to the patient. In case the breast structure is a breast implant, there is also a need for such a supporting prosthesis that would securely hold the breast implant in order to limit the risk of bottoming out of the implant. There is also a need for a prosthesis for supporting a breast structure that would allow the surgeon to try several positions of the prosthesis relative to the breast structure and to the pectoral muscle before secure fixation. The prosthesis should therefore be preferably repositionable.

In this application, the “upper” end, edge or part of an element of a prosthesis is to be understood as meaning the end, edge or part of the element located substantially in the direction of the head of the body when the prosthesis is implanted in the body. The “lower” end, edge or part of an element of a prosthesis is to be understood as meaning the end, edge or part of the element located in the direction of the feet of the body when the prosthesis is implanted in the body. Likewise, in this application, the “vertical direction” is to be understood as meaning the direction aligned on the feet-head axis of a body, and the «horizontal direction» is to be understood as being the transversal direction of the vertical direction in a plane of the prosthesis.

A first aspect of the invention is a prosthesis for supporting a breast structure within a patient, the prosthesis comprising:

a reinforcement part comprising a first fabric made of a first arrangement of biocompatible yarns and configured to receive at least a curve-shaped lower portion of the breast structure, said reinforcement part being intended to be sutured to the chest wall or to the infra-mammary fold, said first arrangement of yarns conferring to said first fabric an elongation under 50N in the vertical direction of E1,

a fixation part comprising a second fabric made of a second arrangement of biocompatible yarns and intended to be fixed to the pectoral muscle, said second arrangement of yarns conferring to said second fabric an elongation under 50N in the vertical direction of E2, and

a transition part comprising a third fabric made of a third arrangement of biocompatible yarns, said transition part connecting together the reinforcement part and the fixation part, said third arrangement of yarns conferring to said third fabric an elongation under 50N in the vertical direction of E3,

wherein E3 is greater than E1 and greater than E2.

In the present application, by arrangement of biocompatible yarns is meant an assembly of yarns, fibres, filaments and/or multifilaments forming a fabric, and for example obtained by knitting, weaving, braiding, or non-woven.

In the present application, “biocompatible” is understood as meaning that the materials having this property can be implanted in the human or animal body.

The prosthesis of the invention may be provided to the user as a textile in a preformed perimeter shape, said textile encompassing the first, second and third fabrics. The prosthesis of the invention is intended to be used as a support of a breast structure in breast reconstructive surgery or in breast lifting surgery and is intended to engage around the breast structure, such as the breast implant or the breast tissue, so as to cup said breast structure, and at least part of its peripheral edge is intended to be sutured either to the chest wall, for example the ribs, and/or to the pectoral muscle. The prosthesis of the invention provides a shape and configuration providing the most support when curved in a supportive engagement with the breast structure.

Because of its structure comprising at least three parts and because of the relative values of the respective elongations under 50N in the vertical direction of these three parts, the prosthesis of the invention allows for stretching and elasticity of the supported breast structure, in a manner very close to the natural behavior of a breast, thereby yielding a more natural appearance and movement during movement such as walking by the patient. The prosthesis of the invention provides excellent support to the multi directional curves of the supported breast structure.

The prosthesis of the invention comprises three parts, one of which, the transition part, shows an elongation under 50N in the vertical direction E3 greater than the elongation under 50N in the vertical direction E1 and E2 of each of the two other parts, namely the reinforcement part and the fixation part. For example, the value of E3 is above the value of E1 and above the value of E2, and E3 may not be equal to E1 and may not be equal to E2.

The elongation under 50N in the vertical direction of each of the three parts of the prosthesis is provided to said part by the arrangement of yarns defining the fabric forming said part. In particular, for each fabric, the elongation under 50N in the vertical direction is dependent both on the nature of the yarns and on the pattern followed by the yarns. For example, the pattern may be a woven pattern or a knitting pattern. It is known that knits and woven structures possess a warp direction and a weft direction. For knits and wovens, elongations under 50N are measured both in the warp and in the weft directions. Depending on the weaving or knitting patterns applied and on the nature of the yarns used, the elongation under 50N in the warp direction may be different from the elongation under 50N in the weft direction for a single fabric.

In the present application, by “elongation under 50N in the vertical direction” for a fabric of the prosthesis of the invention, is meant either the elongation under 50N measured in the warp direction of the fabric or the elongation under 50N measured in the weft direction of the fabric, depending on which direction of the fabric, either warp or weft, is positioned along the vertical direction of the prosthesis.

In the present application, the elongation under 50N in the warp direction and in the weft direction of a fabric is measured according to the method for measuring the tensile breaking strength and elongation at break according to ISO 13934-1: 2013 “Textiles—Tensile properties of fabrics—Part 1: Determination of maximum force and elongation at maximum force using the strip method”, 5 samples, width: 50 mm, Length: 200 mm between the jaws, Crosshead speed: 100 mm/min, Pre-load: 0.5 N, using a traction testing machine such as the Hounsfield model H5KS (Hounsfield, Redhill, England).

The reinforcement part of the prosthesis of the invention is intended to receive the curve-shaped lower portion of a breast implant and is intended to be sutured to the chest wall, for example to the ribs, or to the infra-mammary fold. The reinforcement part of the prosthesis of the invention is therefore intended to behave as a hammock and should have mechanical properties sufficient for contributing to the support of the breast implant against gravity and for example for limiting the risk of bottoming out of the breast implant. In this view, the first fabric forming the reinforcement part should show an elongation under 50N in the vertical direction, also referred to as E1, adapted to hold the breast implant in a relatively steady and reliable manner.

For example, E1 may be equal or less than about 40%. For example E1 may range from about 0 to about 40%, preferably from about 18% to about 35%.

The fixation part of the prosthesis of the invention is intended to be fixed to the pectoral muscle. The fixation part is intended to face the top portion of the breast structure and should show mechanical properties adapted to secure anchorage of the prosthesis in the pectoral muscle. In this view, the second fabric forming the fixation part should show a limited elongation under 50N in the vertical direction, also referred to as E2, so that anchorage in the pectoral muscle and tissue ingrowth are not negatively impaired by an excessive solicitation.

For example, E2 may be equal or less than about 35%. For example E2 may range from about 0% to about 35%, preferably from about 5% to about 15%.

The transition part of the prosthesis of the invention is intended to connect the reinforcement part to the fixation part so as to absorb the tensions created by the mechanical pressures of the supported breast structure and limit the pain felt by the patient, and so as to further allow the supported breast structure to have the most natural mechanical behavior. The transition part may preferably represent a limited area of the whole prosthesis and the third fabric forming the transition part should show an elongation under 50N in the vertical direction, also referred to as E3, adapted to give the supported breast structure some freedom of movement and to absorb gently the tensions generated in the supported breast structure by the movements of daily life. In particular, E3 is greater than E1 and than E2 so as to have the capability to absorb the tensions originating from the first fabric and the second fabric due to the respective functions of support and of fixation of the reinforcement part and of the fixation part.

For example, E3 is equal or greater than about 35%. In embodiments, E3 ranges from about 35% to about 120%, preferably from about 35% to about 70%.

The transition part of the prosthesis of the invention allows the prosthesis to accommodate the curve of the breast structure in a natural and comfortable fashion for the patient. The elongation under 50N in the vertical direction of the third fabric forming the transition part confers to the supported breast structure the required elasticity and stretch to allow the breast structure to move in a natural manner which is comfortable to the patient.

The prosthesis of the invention may be under the form of various embodiments, for example defined by the following features, taken in combination or as alternatives:

E1 may be equal or less than about 40%, for example E1 may range from about 0 to about 40%, preferably from about 18% to about 35%,

E2 may be equal or less than about 35%, for example E2 may range from about 0% to about 35%, preferably from about 5% to about 15%,

E3 may be equal or greater than about 35%, for example E3 may range from about 35% to about 120%, preferably from about 35% to about 70%,

E3 may be more than 20%, 30%, 50%, 100%, 200% greater than E1,

E3 may be more than 50%, 100%, 200%, 500% greater than E2,

where H represents the total height of the prosthesis and h the height of the transition part, measured along the vertical direction, when said prosthesis is in a planar configuration, the ratio h/H ranges from about 1/30 to about 1/2, preferably from about 1/12 to about 1/4,

the reinforcement part may have a globally elongated shape in the horizontal direction, said shape showing a convex lower edge,

the shape of the reinforcement part may show a convex upper edge,

the shape of the reinforcement part may show a concave upper edge,

the transition part may have substantially the shape of a portion of a circular crown,

the lower edge of the shape of the transition part may be the upper edge of the shape of the reinforcement part,

the fixation part may comprise a lower edge from which extend vertically and in the upper direction one or more arm(s) intended to be fixed to the pectoral muscle,

each arm of the fixation part having a lower end and an upper end, said lower end may be substantially larger in the horizontal direction than said upper end,

at least two said arms of the fixation part may extend vertically and in the upper direction,

at least three said arms of the fixation part may extend vertically and in the upper direction,

at least four said arms of the fixation part may extend vertically and in the upper direction,

at least five said arms of the fixation part may extend vertically and in the upper direction,

at least six said arms of the fixation part may extend vertically and in the upper direction,

at least seven said arms of the fixation part may extend vertically and in the upper direction,

at least eight said arms of the fixation part may extend vertically and in the upper direction,

the lower edge of the fixation part may be the upper edge of the shape of the transition part,

a recess may be provided in one or more said reinforcement part, fixation part and transition part, said recess being intended to face the nipple-areola complex when the prosthesis is implanted,

the first fabric may be a porous knit,

the first fabric may be a two-dimensional porous knit,

the first fabric may be a three-dimensional porous knit,

the first fabric may be a porous knit showing pores having a size above 1 mm×1 mm,

the first fabric may show a bursting strength above about 400 kPa,

the yarns forming the first arrangement may be monofilaments,

the yarns forming the first arrangement may be monofilaments having a diameter of less than about 0.3 mm,

the yarns forming the first arrangement may be multifilaments, for example having a linear density of less than about 400 dTex,

the yarns forming the first arrangement may be surface treated with an low friction substance,

a face of the first fabric intended to be in contact with the breast implant may be covered with a low friction coating, for example a low friction film,

the first fabric being a three-dimensional porous knit, a face of said three-dimensional knit intended to be in contact with the breast structure may be covered with a low friction coating, for example a low friction film, and a face of said three-dimensional knit intended to be in contact with the skin may be provided with pores having a size above 1 mm×1 mm,

the height h of the transition part may range from 1 to 5 cm, preferably from 2 to 3 cm,

the third fabric may be a porous knit,

the third fabric may be a two-dimensional porous knit,

the yarns forming the third arrangement may be monofilaments,

the yarns forming the third arrangement may be multifilaments,

the second fabric may be a porous knit,

the second fabric may be a two-dimensional porous knit,

a face of the second fabric intended to face the pectoral muscle may be provided with fastening means capable of fixing at least temporarily said face of said second fabric in the pectoral muscle,

the reinforcement part may be provided with a reinforcement member configured for inducing a curved shape to said first fabric conformable with said curve-shaped lower portion of the breast structure,

the reinforcement member may be an overmolded wire positioned in the area of a lower edge of said reinforcement part,

the reinforcement member may be made from a bioresorbable material,

the reinforcement part may be linked to the transition part by means of sewing, gluing welding, overmolding and combinations thereof,

the transition part may be linked to the fixation part by means of sewing, gluing, welding, overmolding and combinations thereof,

the first, second and third fabrics may be made as a single unitary structure,

h being the height of the transition part, h1 being the height of the reinforcement part, h2 being the height of the fixation part, all measured along the vertical direction when said prosthesis is in a planar configuration, the ratio h/h1 may range from about 1/15 to about 2/1, preferably from about 1/6 to about 1/1, and the ratio h/h2 may range from about 1/15 to about 2/1, preferably from about 1/6 to about 1/1.

In embodiments, wherein H represents the total height of the prosthesis and h the height of the transition part, measured along the vertical direction, when said prosthesis is in a planar configuration, the ratio h/H ranges from about 1/30 to about 1/2, preferably from about 1/12 to about 1/4. Such a ratio allows obtaining the adequate stretch and elasticity for conferring to the prosthesis a behavior close to the natural behavior of a natural breast while not jeopardizing the strength of the support needed to hold the breast structure in place against gravity. In particular, when the breast structure to be supported is a breast implant, such a ratio contributes to avoid bottoming out of the implant and sagging of the reconstructed breast.

The required elongation under 50N in the vertical direction may be provided to each fabric of the prosthesis of the invention by means of use of specific yarns such as elastic yarns, which may be combined or not with conventional non elastic yarns, and/or by means of specific arrangement of yarns, such as the weaving and knitting patterns.

Examples of elastic yarns particularly suitable for the third fabric of the prosthesis of the invention may be selected from the group consisting in polyether amide yarns, polyurethane yarns or thermoplastic elastomer polyethylene terephthalate yarns, having an elongation at break equal to or greater than 75%, measured according to ISO 2321:2006.

For example, non elastic yarns may show an elongation at break of less than 30% measured according to ISO 2062:2010.

The yarns or fibres or filaments, monofilaments and/or multifilaments forming the arrangement of yarns constituting the first, second and third fabrics of the prosthesis according to the invention can be made of any biodegradable or non-biodegradable biocompatible material.

In the present application, “bioresorbable” or “biodegradable” is understood to mean that the materials having this property are absorbed and/or degraded by the tissues or washed from the implantation site and disappear in vivo after a certain time, which may vary, for example, from a few hours to a few years, depending on the chemical nature of the materials.

Thus, the biodegradable materials suitable for the yarns of the first, second and third fabrics of the prosthesis according to the present invention can be chosen from polylactic acid (PLA), polyglycolic acid (PGA), oxidized cellulose, polycaprolactone (PCL), polydioxanone (PDO), trimethylene carbonate (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHAs), copolymers of these compounds and mixtures thereof.

The non-biodegradable materials suitable for the yarns of the first, second and third fabrics of the prosthesis according to the present invention can be chosen from polyethylene terephthalate (PET), polyamides, aramids, expanded polytetrafluoroethylene, polyurethane, polyvinylidene difluoride (PVDF), polybutyl esters, polyetheretherketone (PEEK), polyolefins (such as polyethylene or polypropylene), polyethers, and combinations thereof.

For each fabric, the arrangement of yarns may be a knit, a woven structure, a braid or a non-woven. In embodiments, the fabric of the reinforcement part, the fabric of the fixation part and the fabric of the transition part of the prosthesis of the invention are knits, in particular porous knits.

In the present application, the term “porous knit” is intended to mean a knit which has pores, or gaps, alveoli, holes, orifices, which are evenly or unevenly distributed not only at the surface, but also within the thickness of said knit. Indeed, by virtue of the meshwork of a knit in general, it is possible to obtain openworked faces that promote cell recolonization after implantation, namely a porous knit.

For example, the first knit may be a porous knit. The second fabric may be a porous knit. The third fabric may be a porous knit. In embodiments, each of said first, second and third fabrics are porous knits. The porous knits suitable for the first, second and third fabrics of the prosthesis of the invention may show various knitting patterns conferring to each knit specific mechanical properties.

The porous knits suitable for the prosthesis of the invention may be two-dimensional or three-dimensional.

Within the meaning of the present application, a two-dimensional knit is understood as a knit having two opposite faces linked to each other by meshes but devoid of a spacer giving it a certain thickness: such a knit can be obtained, for example, by knitting yarns on a warp knitting machine or raschel knitting machine using two guide bars. Examples of knitting two-dimensional knits suitable for the present invention are given in the document WO2009/071998.

According to the present application, a three-dimensional knit is understood as a knit having two opposite faces linked to each other by a spacer that gives the knit a significant thickness, said spacer itself being formed from additional linking yarns in addition to the yarns forming the two faces of the knit. Such a knit can be obtained, for example, on a double-bed warp knitting or raschel knitting machine using several guide bars. Examples of knitting three-dimensional knits suitable for the present invention are given in the documents WO99/05990, WO2009/031035 and WO2009/071998.

The first fabric may be a two-dimensional porous knit. A two-dimensional knit may confer a good mechanical strength to the first fabric and therefore to the reinforcement part.

Alternatively, the first fabric may be a three-dimensional porous knit. A three-dimensional porous knit allows a high degree of differentiation of its two opposite faces and therefore allows providing a knit having a first property on a first face, such as for example a smooth surface for contact with the breast structure such as a breast implant, and having a different property on its opposite face, such as a porosity adapted for promoting cell growth with regards to the facing skin tissues.

In embodiments, the first fabric is a porous knit showing pores having a size above 1 mm×1 mm. For example, the pore size of the porous knit forming the third fabric may range from 1 mm×1 mm to 3 mm×3 mm.

In the present application, the pore size (width×height) (mm) is measured according to the following method: knit biggest pores are measured making one measurement on 10 individual samples with a profile projector such as a projector 300V from ORAMA.

The first fabric forming the reinforcement part is intended to be positioned between the breast structure and the skin once the prosthesis is implanted. The presence of large pores on the face of the knit forming the first fabric intended to face the skin will favor cell colonization once the prosthesis is implanted.

In embodiments, the first fabric shows a thickness ranging from 0.2 mm to 2.5 mm. Such a thickness allows the reinforcement part to be less palpable under the skin, thereby conferring to the patient a natural feeling regarding the supported breast structure.

In embodiments, the first fabric shows a bursting strength above about 400 kPa.

In the present application, the bursting strength (kPa) is measured according to ISO 13938-2: 1999 “Textiles—Bursting properties of textiles—Pneumatic method for determining the bursting strength and bursting deformation”, 5 samples.

Such a bursting strength allows the reinforcement part to complete adequately its function of support. In particular, such a bursting strength allows the reinforcement part to hold securely the breast structure, even when the patient performs significant movement of the daily life, such as jumping, and to compensate the undesired effect of gravity on the breast structure.

In embodiments, the first fabric shows a suture pull out strength in the warp direction and in the weft direction above about 15N, preferably above about 35N.

In the present application, the suture pull out strength in the warp direction and in the weft direction is measured according to NF S94-801: 2007 “Reinforcement implants introduced by the vaginal route for the treatment of stress urinary incontinence and/or of prolapse of the pelvic organs—pre-clinical trials and clinical trials”—§ 5.3.3 5 specimens 50×100 mm, USP 2 suture yarn, crosshead speed: 100 mm/min, using a traction testing machine such as the Hounsfield model H5KS (Hounsfield, Redhill, England).

Such a suture pull out strength in the warp direction and in the weft direction allows in particular the reinforcement part to be sutured in a reliable manner to the chest wall, for example the ribs, or to the infra-mammary fold.

In embodiments, the first fabric shows a tear strength in the warp direction and in the weft direction above about 25N, preferably above about 32N.

In the present application, the tear strength (N) in the warp direction and in the weft direction is measured according to ISO 4674:1977 “Textiles covered with rubber or plastic—Determination of the tear strength” Method A2, 5 samples, width: 75 mm, Tear length ≤145 mm, crosshead speed: 100 mm/min.

Such a tear strength in the warp direction and in the weft direction allows in particular the reinforcement part to resist efficiently to tensions generated in the breast structure, in particular in the reconstructed breast by the weight of the breast implant.

The yarns forming the first arrangement may be any biocompatible yarns known for forming surgical meshes, such as fibers, monofilaments, multifilaments and combinations thereof.

In embodiments, the yarns forming the first arrangement are multifilaments. Multifilaments may provide a soft touch to the knit and allow obtaining a more natural palpation feeling as well as a more natural appearance of the supported breast structure.

In embodiments, the yarns forming the first arrangement are monofilaments. For example, the monofilaments forming the first arrangement show a diameter of less than about 0.3 mm. Such monofilaments with a small diameter are less palpable under the skin and therefore confer a more natural feeling on the skin of the patient.

A first example of a porous knit suitable for forming a first fabric for the reinforcement part of the prosthesis of the invention is a knit obtained by knitting a monofilament yarn of polyethylene terephthalate of diameter 0.08 mm on a double bed knitting machine with four guide bars, GBII, GBIII, GBIV and GBV, according to the following pattern, according to ISO 11676 standard:

GBII: 4.3.2.2/1.0.1.1/1.2.1.1/1.0.1.1/1.2.1.1/1.0.1.1/1.2.3.3/4.5.4.4/4.3.4.4/4.5.4.4/4.3.4.4/4.5.4.4//

GBIII: 3.4.8.9/6.7.6.6/6.5.6.6/6.7.6.6/6.5.6.6/6.7.6.6/6.5.1.0/3.2.3.3/3.4.3.3/3.2.3.3/3.4.3.3/3.2.3.3//

GBIV: 4.4.4.3/2.2.1.0/1.1.1.2/1.1.1.0/1.1.1.2/1.1.1.0/1.1.1.2/3.3.4.5/4.4.4.3/4.4.4.5/4.4.4.3/4.4.4.5//

GBV: 1.1.1.2/3.3.4.5/4.4.4.3/4.4.4.5/4.4.4.3/4.4.4.5/4.4.4.3/2.2.1.0/1.1.1.2/1.1.1.0/1.1.1.2/1.1.1.0//

This knit is a three-dimensional knit and will be referred to hereinafter as Knit X.

Knit X shows the following properties, measured according to the methods as described in the present application:

E1: 25%, corresponding to the elongation under 50N of the knit in the warp direction of the knit.

Elongation under 50N of the knit in the weft direction: 40%

Bursting strength: 415 kPa

Suture pull out strength in the warp direction and in the weft direction: 37 N

Tear strength in the warp direction and in the weft direction: 35N

Pore size: 2.1 mm×3.0 mm

Another example of a porous knit suitable for forming a first fabric for the reinforcement part of the prosthesis of the invention is a knit obtained by knitting a multifilament yarn of polyethylene terephthalate of 50 dTex on a double bed knitting machine with six guide bars, GBI, GBII, GBIII, GBIV, GBV and GBVI, according to the following pattern, according to ISO 11676 standard:

GBI: 1.2.1.1/1.0.1.1/1.2.1.1/1.0.1.1/1.2.2.2/3.2.2.2/1.2.2.2/3.2.2.2//

GBII: 1.2.2.2/3.2.2.2/1.2.2.2/3.2.2.2/1.2.1.1/1.0.1.1/1.2.1.1/1.0.1.1//

GBIII: 0.1.0.1/0.0.0.0//

GBIV: 0.1.0.1/0.0.0.0//

GBV: 1.1.0.1/1.1.2.1/1.1.0.1/11.1.2.1/2.2.2.3/2.2.2.1/2.2.2.3/2.2.2.1//

GBVI: 2.2.2.3/2.2.2.1/2.2.2.3/2.2.2.1/1.1.0.1/1.1.2.1/1.1.0.1/1.1.2.1//

This knit is a three-dimensional knit and will be referred to hereafter as Knit Y.

Knit Y shows the following properties measured according to the methods as described in the present application:

E1: 19%, corresponding to the elongation under 50N of the knit in the warp direction of the knit.

Elongation under 50N of the knit in the weft direction: 44%

Bursting strength: 321 kPa

Suture pull out strength in the warp direction, respectively in the weft direction: 24N, respectively 33 N.

Tear strength in the warp direction and in the weft direction: 20 N

Pore size: 1.9 mm×2.4 mm

Another example of a porous knit suitable for forming a first fabric for the reinforcement part of the prosthesis of the invention is a knit obtained by knitting a monofilament yarn of polypropylene of a diameter of 0.10 mm on a double bed knitting machine with four guide bars, GBII, GBIII, GBIV and GBV, according to the following pattern, according to ISO 11676 standard:

GBII: 0.1.1.1/1.2.2.2/3.4.4.4/5.4.4.4/4.3.3.3/2.1.1.1//

GBIII: 5.4.4.4/4.3.3.3/2.1.1.1/0.1.2.1/1.2.2.2/3.4.4.4//

GBIV: 4.4.5.4/4.4.4.3/3.3.2.1/11.1.0.1/1.1.1.2/2.2.3.4//

GBV: 1.1.0.1/1.1.1.2/2.2.3.4/4.4.5.4/4.4.4.3/3.3.2.1//

This knit is a three-dimensional knit and will be referred to hereafter as Knit Z.

Knit Z shows the following properties measured according to the methods as described in the present application:

E1: 35%, corresponding to the elongation under 50N of the knit in the warp direction of the knit.

Elongation under 50N of the knit in the weft direction: 45%

Bursting strength: 646 kPa

Suture pull out strength in the warp direction and in the weft direction: 60 N

Tear strength in the warp direction and in the weft direction: 43 N

Pore size: 1.5 mm×1.5 mm

In embodiments, the yarns forming the first arrangement are surface treated with a low friction substance.

Within the meaning of the present application, “low friction” is understood as a smooth biocompatible material or coating.

Such embodiments allow obtaining a first fabric showing a low friction surface. The contact between the first fabric of the reinforcement part and the breast structure, for example the surface of the breast implant, will therefore be facilitated and will not favor friction, thereby limiting potential erosion with time.

Low friction substance for treating the yarns of the first arrangement may be selected from silicone, collagen and combinations thereof. Biocompatible spinning oil used in the textile field may also be used as a low friction substance for treating the yarns of the first arrangement.

Alternatively or in combination, a face of the first fabric intended to be in contact with the breast structure may be covered with a low friction coating, for example a low friction film. Such embodiments will favor easy contact between the surface of the breast structure, for example the breast implant and the first fabric and will limit erosion between these two elements. Potential degradation of the breast structure at the contact of the reinforcement part over time will therefore be avoided or limited.

A low friction film suitable for coating the face of the first fabric intended to be in contact with the breast structure may for example be a collagen film. Films obtained by extrusion from a copolymer of glycolide, caprolactone, trimethylene carbonate and lactide may also be used as a low friction film for coating the face of the first fabric intended to be in contact with the breast structure.

In embodiments, the first fabric is a three-dimensional porous knit, and a face of said three-dimensional knit intended to be in contact with the breast structure is covered with a low friction coating, for example a low friction film, and a face of said three-dimensional knit intended to be in contact with the skin is provided with pores having a size above 1 mm×1 mm. Such embodiments allow having different properties on each face of the knit, each property being in harmony with the function said face of the knit is intended to perform. The thickness of the three dimensional knit allows differentiating significantly the two opposite faces of the knit. As such, the face of the knit intended to be in contact with the breast structure is provided with a smooth surface thanks to the presence of the low friction coating and will enable a smooth contact with the breast structure, for example the breast implant, limiting the risk of erosion and degradation of the breast structure over time. Moreover, simultaneously, the large pores of the face of the knit intended to face the skin will favor cell colonization and cell growth within the three-dimensional knit.

The second fabric, which forms the fixation part, may be a two-dimensional porous knit. A two-dimensional knit may confer a good mechanical strength to the second fabric and therefore to the fixation part.

In particular, for the second fabric, it is possible to use patterns, such as chain stitched patterns, that are known for producing “blocked” knit, in other words knits usually showing a very low elongation at break, when only non elastic yarns are used. Such patterns producing “blocked knits” are useful when mechanical properties such as a good suture pull out and a good tear strength are needed. Such patterns produce fabrics having good mechanical resistance and limited elongation under 50N in the weft and warp directions.

In embodiments, the second fabric is a porous knit showing pores having size above 1 mm×1 mm. For example, the pore size of the porous knit forming the second fabric may range from 1 mm×1 mm to 3 mm×3 mm.

The second fabric forming the fixation part is intended to be positioned between the breast implant and the pectoral muscle once the prosthesis is implanted. The presence of large pores on the face of the knit forming the second fabric intended to face the pectoral muscle will favor cell colonization once the prosthesis is implanted.

In embodiments, the second fabric shows a thickness ranging from 0.2 mm to 2.5 mm. Such a thickness allows the fixation part to be less palpable under the skin, thereby conferring to the patient a natural feeling regarding the supported breast structure.

In embodiments, the second fabric shows a suture pull out strength in the warp direction and in the weft direction above about 20 N, preferably above about 30 N.

Such a suture pull out strength in the warp direction and in the weft direction allows in particular the fixation part to be sutured in a reliable manner to the pectoral muscle.

In embodiments, the second fabric shows a tear strength in the warp direction and in the weft direction above about 15 N, preferably above about 18 N.

Such a tear strength in the warp direction and in the weft direction allows in particular the fixation part to resist efficiently to tensions generated into said fixation part by the effect of gravity on the breast structure.

In embodiments, a face of said second fabric intended to face the pectoral muscle is provided with fastening means capable of fixing at least temporarily said face of said second fabric in the pectoral muscle. For example, these fastening means are barbs protruding from the face of the second fabric intended to be positioned in regards of the pectoral muscle. These fastening means or barbs can protrude from said face of said second fabric in a manner substantially perpendicular to the plane of said face or, alternatively, in one or more planes inclined with respect to the plane of said face. These barbs are intended to function as fixing means by anchoring themselves in the pectoral muscle.

By virtue of the fastening means, such as barbs, the second fabric of the prosthesis of the invention fixes naturally at least temporarily to the pectoral muscle. In particular, the surgeon may grip and ungrip the second fabric to the pectoral muscle as many times as necessary until he determines, optionally with the help of the patient, the right position for the fixation.

The fastening means, for example the barbs, of the second fabric of the prosthesis according to the invention can be formed from yarns, for example hot-melt monofilament yarns issuing directly from the arrangement of yarns forming the fabric. Fabrics and barbs of this kind, and the method of producing them, are described, for example, in the applications WO01/81667 and DE 198 32 634 or in the U.S. Pat. Nos. 6,596,002 and 5,254,133.

For example, the barbs are formed from monofilament yarns made of polylactic acid.

Alternatively, the fastening means, for example the barbs, of the second fabric of the prosthesis according to the invention can be any kind of hook made entirely from biocompatible material and integral with the arrangement of yarns forming said fabric, irrespective of whether these hooks have been incorporated in said fabric during the manufacture (braiding, knitting, weaving, etc.) of said arrangement of yarns or have been attached later.

Knits with barbs suitable for the second fabric of the prosthesis of the present invention are described in WO01/81667, for example, or are also commercially available from the company Sofradim Production under the trade name Parietex® Progrip or Parietene® Progrip.

In one embodiment, the second fabric is a knit based on at least a first yarn of biocompatible polymer material defining a first and second faces of the second fabric and at least a second biocompatible hot-melt monofilament yarn forming said fastening means by melting of loops generated by said second yarn, the pattern followed for knitting said first and second yarns on a warp knitting machine with three guide bars B1, B2, B3 being the following, according to the standard ISO 11676:

Bar B1: 1.0/0.1//

Bar B2: 1.0/7.7/6.6/7.7//

Bar B3: 2.1/5.5/3.4/0.0//

said second yarn following the pattern chart of bar B3.

This knit is a two-dimensional knit and will be referred to as Knit F. Knit F shows the following properties:

E2: 5%, corresponding to the elongation under 50N of the knit in the warp direction.

Elongation under 50N of the knit in the weft direction: 15%

Suture pull out strength in the warp direction and in the weft direction: 44 N in the warp direction, and 30 N in the weft direction

Tear strength in the warp direction and in the weft direction: 28 N in the warp direction and 18 N in the weft direction

Pore size: 1.8 mm×1.8 mm

The third fabric, which forms the transition part, may be a two-dimensional porous knit. A two-dimensional knit may confer a good mechanical strength to the second fabric and therefore to the transition part.

In embodiments, the third fabric shows an elongation under 50 N in the warp direction equal or greater than about 35%. In embodiments, the third fabric shows an elongation under 50 N in the warp direction ranging from about 35% to about 120%.

In embodiments, the third fabric shows an elongation under 50 N in the weft direction equal or greater than about 35%. In embodiments, the third fabric shows an elongation under 50 N in the weft direction ranging from about 35% to about 120%.

Such elongation under 50 N in the weft direction and in the warp direction allow the third fabric to show an elongation under 50 N in the vertical direction of at least 35% and to confer to the transition part the required elasticity and stretch to perform its function of absorbing the tensions generated by the supported breast structure.

In embodiments, the third fabric is a porous knit showing pores having a size above 1 mm×1 mm. For example, the pore size of the porous knit forming the third fabric may range from 1 mm×1 mm to 3 mm×3 mm.

The third fabric forming the transition part is intended to be positioned between the breast structure and a lower region of the pectoral muscle once the prosthesis is implanted. The presence of large pores on the face of the knit forming the third fabric intended to face the lower region of the pectoral muscle will favor cell colonization once the prosthesis is implanted.

In embodiments, the third fabric shows a tensile breaking strength in the warp direction and in the weft direction equal or greater than 115 N. In embodiments, the third fabric shows a tensile breaking strength in the warp direction and in the weft direction ranging from 115 N to 350 N.

In the present application, the tensile breaking strength in the warp direction and in the weft direction is measured according to the following method: Tensile breaking strength and elongation at break: is measured according to ISO 13934-1: 2013 “Textiles—Tensile properties of fabrics—Part 1: Determination of maximum force and elongation at maximum force using the strip method”, 5 samples, width: 50 mm, Length: 200 mm between the jaws, Crosshead speed: 100 mm/min, Pre-load: 0.5 N, using a traction testing machine such as the Hounsfield model H5KS (Hounsfield, Redhill, England).

Such a tensile breaking strength in the warp direction and in the weft direction allows the transition part to complete adequately its function of support.

In embodiments, the third fabric shows a thickness ranging from 0.2 mm to 2.5 mm. Such a thickness allows the transition part to be less palpable under the skin, thereby conferring to the patient a natural feeling regarding the supported breast structure.

In embodiments, the yarns forming the third arrangement are monofilaments. Monofilaments allow obtaining a more natural appearance of the reconstructed breasts and also a more natural palpation feeling. Such monofilaments are less palpable and therefore confer a more natural feeling on the skin of the patient.

Elastic yarns may be used to provide the required elongation under 50N in the vertical direction for the third fabric. Alternatively or in combination, the weaving pattern or the knitting pattern may provide the required elongation under 50N in the vertical direction for the third fabric.

A first example of a porous knit suitable for forming a third fabric for the transition part of the prosthesis of the invention is a two-dimensional porous knit as described in WO2011/042811, namely obtained by knitting a monofilament of polyethylene terephthalate of diameter 0.08 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:

Bar B1: 1.0/1.2/1.0/2.3/2.1/2.3/4.5/4.3/4.5/3.2/3.4/3.2//

Bar B2: 4.5/4.3/4.5/3.2/3.4/3.2/1.0/1.2/1.0/2.3/2.1/2.3//

Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.

This knit will hereinafter be referred to as Knit A.

Another example of a porous knit suitable for forming a third fabric for the transition part of the prosthesis of the invention is a two-dimensional knit as described in U.S. Pat. No. 6,408,656, namely obtained by knitting a monofilament of polypropylene of diameter 0.10 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:

Bar B1: 5.4/4.3/2.1/0.1/1.2/3.4//

Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//

Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.

This knit will hereinafter be referred to as Knit B.

Another example of a porous knit suitable for forming a third fabric for the transition part of the prosthesis of the invention is a two-dimensional knit obtained by knitting a monofilament of polypropylene of diameter 0.12 mm knitted on a warp knitting machine having two guide bars B1, B2, the pattern followed being the following, according to the ISO 11676 standard:

Bar B1: 1.2/4.5/4.3/4.5/4.3/1.0/1.2/1.0//

Bar B2: 4.3/1.0/1.2/1.0/1.2/4.5/4.3/4.5//

Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.

This knit will hereinafter be referred to as Knit C.

The properties of Knits A, B and C measured according to the measuring methods described hereinabove are collected in the following table:

Knit A
Knit B
Knit C

Warp
Weft
Warp
Weft
Warp
Weft

Tensile breaking strength (N)
175 ± 12
129 ± 2
187 ± 16
149 ± 10
237 ± 6
201 ± 6

Elongation under 50 N (%)
54 ± 0
50 ± 6
43 ± 1
59 ± 1
38 ± 1
46 ± 0

Thickness (mm)
0.4
0.4
0.6

Pore size (mm) (width ×
1.5 × 1.5
1.6 × 1.4
2.0 × 2.4

height)

In embodiments, depending on which direction, warp or weft, may be selected to position Knit A as the third fabric of the prosthesis of the invention with respect to the vertical direction, E3 may either be 54% or 50%. In other embodiments, depending on which direction, warp or weft, may be selected to position Knit B as the third fabric of the prosthesis of the invention with respect to the vertical direction, E3 may either be 43% or 59%. In other embodiments, depending on which direction, warp or weft, may be selected to position Knit C as the third fabric of the prosthesis of the invention with respect to the vertical direction, E3 may either be 38% or 46%.

The reinforcement part is intended to receive the curve-shaped lower portion of a breast structure. In embodiments, the reinforcement part has a globally elongated shape in the horizontal direction, said shape showing a convex lower edge. Said shape may show a convex upper edge. Alternatively, said shape may show a concave upper edge.

The first fabric forming the reinforcement part of the prosthesis according to the invention may preferably have a generally elongate shape, for example oval or elliptic. The first fabric can have another initial shape and can then be cut to such an elongate shape, in particular to a shape adapted to the function of the reinforcement part. In particular, the shape of the first fabric of the prosthesis of the invention comprises a part capable of efficiently receiving the curved-shape lower portion of a breast structure. The first fabric is essentially delimited by a lower edge and an upper edge. The lower edge is preferably convex in order to optimize the conformity of the first fabric with the curved shape of the lower portion of the breast structure and the suturability of said first fabric to the chest wall. As such, the general shape of the lower edge is preferably convex.

In embodiments, the reinforcement part is provided with a reinforcement member configured for inducing a curved shape to said first fabric conformable with said curve-shaped lower portion of the breast structure. Such embodiments limit the risk of undesired pleating that may occur when implanting a textile over a rounded breast implant.

The reinforcement member may be a rigid or semi-rigid wire having a resiliency or elasticity allowing it to be deformed under the effect of a temporary stress. According to the present invention, the reinforcement member may have an initial curved state allowing the first fabric, and therefore the reinforcement part, to adopt a shape conformable to the curved shape of the lower portion of the breast structure.

The reinforcement member, such as a wire, of the prosthesis according to the invention may be substantially set back from the lower edge of the reinforcement part/first fabric.

The materials that may be suitable for producing the reinforcement member of the prosthesis according to the invention may be chosen from any biocompatible material having a certain rigidity and a certain resilience in order to meet the requirements described above.

In one embodiment, the reinforcement member, for example the wire, is made of a bioresorbable material. For example, the bioresorbable material can be chosen from among polylactic acid (PLA), polycaprolactones (PCL), polydioxanones (PDO), trimethylene carbonates (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHA), oxidized cellulose, polyglycolic acid (PGA), copolymers of these materials and mixtures thereof. For example, the bioresorbable material can be a copolymer of polylactic acid and of polyglycolic acid.

Alternatively, the reinforcement member of the prosthesis according to the invention is made of a non-bioresorbable material chosen from among polypropylenes, polyesters such as polyethyleneterephthalates, polyamides, silicones, polyether ether ketone (PEEK), polyether ketone ketone (PEKK), polyarylether ether ketone (PAEK), polyurethanes and mixtures thereof.

In another embodiment, said reinforcement member is formed by a combination of bioresorbable material and of non-bioresorbable material.

In one embodiment, the reinforcement member of the prosthesis according to the invention is an overmolded wire positioned in the area of a lower edge of said reinforcement part.

The reinforcement member may also be used to help suturing the reinforcement part to the chest wall or to the infra-mammary fold.

The transition part connects the reinforcement part to the fixation part. In embodiments, the transition part has substantially the shape of a portion of a circular crown. For example, a lower edge of said portion of a circular crown is also said upper edge of said shape of said reinforcement part.

In embodiments, the height h of the transition part ranges from 1 to 5 cm, preferably from 2 to 3 cm. Such embodiments allow providing to the entire prosthesis an elasticity and stretch allowing it to behave similarly to biological breast tissues, while not jeopardizing the tensile strength necessary to the prosthesis for performing its support function.

The fixation part is intended to be fixed to the pectoral muscle. In embodiments, said fixation part comprises a lower edge from which extend vertically and in the upper direction one or more arm(s) intended to be fixed to the pectoral muscle. Each arm having a lower end and an upper end, said lower end may be substantially larger in the horizontal direction than said upper end. Each arm may therefore have a substantially triangular shape. In embodiments, at least two said arms extend vertically and in the upper direction. For example, at least three said arms may extend vertically and in the upper direction. In embodiments, at least four said arms extend vertically and in the upper direction. For example, at least five said arms extend vertically and in the upper direction. In embodiments, at least six, seven or eight said arms extend vertically and in the upper direction.

The number of arm(s), their position and their shape allow inducing a conical shape to the fixation part. In particular, the surgeon does not need to cut the second fabric in order to arrange the fabric in a conical manner. Indeed, thanks to the lower end of each arm being substantially larger in the transverse direction than its upper end, the surgeon can easily form a conical mesh that conforms to the conical-like shape of the top of the breast structure.

In embodiments, said lower edge of said second fabric is also an upper edge of said portion of a circular crown.

In embodiments, the reinforcement part is linked to the transition part by means of sewing, gluing, welding, overmolding and combinations thereof. Alternatively, the reinforcement part and the transition part, and in particular the first fabric and the third fabric, may be made as a single structure. In embodiments, the transition part is linked to the fixation part by means of sewing, gluing welding, overmolding and combinations thereof. Alternatively, the transition part and the fixation part, and in particular the second fabric and the third fabric, may be made as a single structure.

Alternatively, the reinforcement part, the transition part and the fixation part, and in particular the first, second and third fabrics, are made as a single unitary structure. For example, using a knitting machine and the proper knitting pattern and/or yarn, the whole prosthesis, namely the reinforcement part, fixation part and transition part, and more particularly the first, second and third fabrics may be knitted and formed as a single unitary structure requiring no sewing or cutting. Such embodiment allows a very natural appearance as significant thickness variations or fabric ridges are thereby avoided.

In embodiments, a recess is provided in one or more of said reinforcement part, fixation part and transition part, said recess being intended to face the nipple-areola complex when the prosthesis is implanted. Such embodiments allow preserving the nipple-areola complex when a prosthesis of the invention is implanted in order to lift up breast tissue. Moreover, such embodiment allows facilitating the reconstruction of the nipple-areola complex further to the implantation of a breast implant and of the prosthesis of the invention. Indeed, the reconstruction of the nipple-areola complex usually takes place once the breast implant and the prosthesis of the invention are implanted and for example once cell colonization has already taken place. The presence of the recess in the prosthesis of the invention avoids an additional thickness in the area of the nipple-areola complex and leaves free said area. The surgeon does not have to take the prosthesis into account in this area when he proceeds to the reconstruction of the nipple-areola complex.

The prosthesis of the invention may be provided in a kit of prosthesis pieces, with each of the plurality of prosthesis pieces in the kit being of varying sizes (sizes may include small, medium, large, etc. . . . or may conform to well known bra sizes).

A second aspect of the present invention is a method for implanting a prosthesis of the invention for supporting a breast structure, such as a breast implant or breast tissue, comprising the following steps:

a) making an incision in the area of the infra-mammary fold,

b) if a breast implant is needed, positioning said breast implant between the chest wall and the pectoral muscle after desinsertion of the pectoral muscle,

c) positioning the prosthesis described above so that the curve-shaped lower portion of the breast structure is received in the reinforcement part, with a lower edge of the reinforcement part facing the chest wall, and an upper area of the fixation part facing the pectoral muscle,

d) suturing the lower edge of the reinforcement part to the chest wall or to the infra-mammary fold,

e) determining the best position of the fixation part with respect to said pectoral muscle,

f) fixing the fixation part to the pectoral muscle,

g) closing the incision.

For example, step e) may be completed by gripping and ungripping said fixation part as many times as necessary with the help of the barbs of said second fabric.

The method of the invention may be used in case of a reconstruction of a breast post mastectomy or for an oncoplastic surgery as a mastopexy post lumpectomy. The method of the invention may also be used for lifting up healthy breast tissue in pure aesthetic surgery.

BRIEF DESCRIPTION OF THE DRAWINGS

The prosthesis and method of the invention will now be further described in reference to the following description and attached drawings in which:

FIG. 1 is a side view of a healthy breast,

FIG. 2 is a side view of a reconstructed breast comprising a breast implant only,

FIG. 3 is a front view of a first embodiment of a prosthesis according to the invention,

FIG. 4 is a front view of a second embodiment of a prosthesis according to the invention,

FIG. 5 is a front view of a third embodiment of a prosthesis according to the invention,

FIG. 6 is a front view of a fourth embodiment of a prosthesis according to the invention,

FIG. 7 is a front view of a fifth embodiment of a prosthesis according to the invention,

FIG. 8 is a front view of a sixth embodiment of a prosthesis according to the invention,

FIG. 9 is a front view of a seventh embodiment of a prosthesis according to the invention,

FIG. 10 is a side view of a prosthesis of FIGS. 3-9 implanted within a patient for supporting a breast implant,

FIG. 11 is a front view of another embodiment of a prosthesis according to the invention,

FIG. 12 is a side view of the prosthesis of FIG. 11 implanted within a patient for supporting breast tissue.

DETAILED DESCRIPTION OF THE EMBODIMENTS

With reference to FIGS. 3-8 are shown embodiments of a prosthesis 100 of the invention. As will appear from the description below, the prosthesis 100 is intended to be implanted into a female patient in a view of supporting a breast implant 12 (see FIG. 10) in breast reconstruction post mastectomy or in a view of supporting breast tissue (see FIGS. 11 and 12) in breast lifting aesthetics surgery.

With reference to FIGS. 3-8, the prosthesis 100 comprises three parts, a reinforcement part 101, a fixation part 102 and a transition part 103. The reinforcement part 101 is configured to receive at least a curve-shaped lower portion of a breast structure and is intended to be sutured to the chest wall or to the infra-mammary fold. The fixation part 102 is intended to be fixed to the pectoral muscle. The fixation part 102 will usually be surrounding the top conical portion of the breast structure (see FIGS. 10 and 11). The transition part 103 connects the reinforcement part 101 to the fixation part 102.

With reference to FIGS. 3-8 the reinforcement part 101 has a globally elongated shape in the horizontal direction, said shape showing a convex lower edge 104. The shape of the reinforcement part 101 is suited to engage over the lower or bottom curve portion of a breast structure in a manner to cup or otherwise support the structure in a bra-like fashion. The reinforcement part 101 will form the bottom part of the prosthesis and its lower edge is substantially an arch shaped perimeter edge, using a predetermined depth or arc corresponding to the natural shape of breast.

The convex lower edge 104 of the reinforcement part therefore allows encompassing the lower portion of a breast structure while remaining close to the chest wall or to the infra-mammary fold. As will appear later in the description, the lower edge 104 of the reinforcement part 101 is intended to be sutured or fixed to the chest wall or to the infra-mammary fold once the prosthesis 100 is implanted.

For example, the shape of the reinforcement part 101 may be generally oval or elliptical as shown on FIGS. 5-7. In such a case, the shape of the reinforcement part shows a convex upper edge 105.

Alternatively, the shape of the reinforcement part 101 may show a concave upper edge 105, as shown on FIGS. 3, 4 and 8. For example, the reinforcement part 101 may have a crescent shape, as shown on FIGS. 3 and 4. With reference to FIG. 8, the concave upper edge 105 of the reinforcement part 101 may show an additional concave curve 108.

With reference to FIG. 9, the fabric used for forming the reinforcement part 101 may have another initial shape and can then be cut to such an elongate shape, in particular to a shape adapted to the function of the reinforcement part.

With reference to FIGS. 3-9, the transition part 103 connects the reinforcement part 101 to the fixation part 102. The transition part 103 may have substantially the shape of a portion of a circular crown. In particular, the transition part 103 shows a height h (see FIG. 6) in the vertical direction substantially constant. In this view, the lower edge 106 and the upper edge 107 of the transition part 103 are substantially parallel to each other.

Indeed, as will appear later in the description, the transition part 103 possesses an elongation greater than the elongation of the reinforcement part 101 and of the fixation part 102, so that stretch and elasticity close to the natural behavior of a healthy breast is conferred to the supported breast structure. In this view, having a substantially constant height h of the transition part 103 allows maintaining a relatively constant stretch feeling along the horizontal direction of the prosthesis 100, and therefore of the supported breast structure.

For example, the lower edge 106 of the portion of a circular crown forming the transition part 102 is also the upper edge 105 of the reinforcement part 101. With reference to FIGS. 3, 4, 8 and 9, the lower edge 106 and the upper edge 107 of the transition part 103 show therefore a concave shape. With reference to FIG. 8, the lower edge 106 and the upper edge 107 of the transition part 103 are not substantially parallel as the lower edge 106 of the transition part 103 comprises the concave curve 108, whereas the upper edge 107 does not include any additional curve.

On the contrary, with reference to FIGS. 5-7, the lower edge 106 and the upper edge 107 of the transition part 103 show therefore a convex shape.

In embodiments, H represents the total height of the prosthesis 100 and h the height of the transition part 103, along a vertical direction, when the prosthesis 100 is in a planar configuration, for example as shown on FIG. 6, the ratio h/H ranges from about 1/30 to about 1/2, preferably from about 1/12 to about 1/4.

In embodiments, the height h of the transition part ranges from 1 to 5 cm, preferably from 2 to 3 cm.

Such embodiments allow providing to the entire prosthesis an elasticity and stretch allowing it to behave similarly to biological breast tissues, while not jeopardizing the mechanical properties necessary for the prosthesis to perform its support function.

The fixation part 102 forms the upper part of the prosthesis 100 and is intended to be fixed to the pectoral muscle once the prosthesis 100 is implanted (see FIGS. 10 and 11). The fixation part 102 may have any shape as long as said shape provides sufficient surface for overlapping an area of the pectoral muscle sufficient for ensuring a reliable fixation between the fixation part 102 and the pectoral muscle. For example, with reference to FIGS. 3-9, the fixation part 102 comprises a lower edge 109 from which extend vertically and in the upper direction one or more arm(s) 110 intended to be fixed to the pectoral muscle.

The arms 110 have a lower end 111 and an upper 112. Preferably, the lower 111 is larger in the horizontal direction than the upper 112, in order to ensure better resistance against gravity and better fixation. With reference to FIGS. 8 and 9, the lower ends 111 of the arms 110 form a continuous strip 113.

With reference to FIGS. 3 and 5, two arms 110 extend from the lower edge 109 of the fixation part 102 in the upper direction. With reference to FIGS. 4, 7 and 8, four arms 110 extend from the lower edge 109 of the fixation part 102 in the upper direction. With reference to FIGS. 6 and 9, five 110 extend from the lower edge 109 of the fixation part 102 in the upper direction.

The number of arms 110 may be varying from one up to ten, as long as said arms provide the necessary surface and strength for ensuring a reliable fixation to the pectoral muscle.

In addition, the shape and number of arms 110 allow shaping the fixation part 102 in a three-dimensional manner, in order to conform to the conical shape of the top portion of the breast structure. Thanks to the substantially triangular shape of the arms 110 and to their number preferably greater than one, pleats are avoided when the surgeon shapes the fixation part 102 in conformity with the three dimensional shape of the breast structure.

With reference to FIGS. 5, 7 and 9 is shown a recess 114 provided in the prosthesis. The recess 114 may be provided in the transition part 103 (see FIG. 9) or may be part of the fixation part 103 and of the transition part 102 as shown on FIGS. 5 and 7. The recess 114 is intended to face the nipple-areola complex when the prosthesis 100 is implanted. The presence of the recess 114 in the prosthesis 100 avoids an additional thickness in the area of the nipple-areola complex and leaves free this area when the surgeon proceeds to the reconstruction of nipple-areola complex if needed.

With reference to FIGS. 7 and 8 is shown a reinforcement member under the form of a wire 115, provided in the lower region of the reinforcement part 101. The wire 115 is configured for inducing a curved shape to the reinforcement part 101 conformable with the curve-shaped lower portion of the breast structure. The wire 115 is substantially set back from the lower edge of the reinforcement part 101.

The materials that may be suitable for producing the wire 115 may be chosen from any biocompatible material having a certain rigidity and a certain resilience in order to meet the requirements described above.

In one embodiment, the wire is made of a bioresorbable material. For example, the bioresorbable material can be chosen from among polylactic acid (PLA), polycaprolactones (PCL), polydioxanones (PDO), trimethylene carbonates (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHA), oxidized cellulose, polyglycolic acid (PGA), copolymers of these materials and mixtures thereof. For example, the bioresorbable material can be a copolymer of polylactic acid and of polyglycolic acid. Such embodiments allow avoiding that foreign material stay too long a time in the body of the patient.

Alternatively, the wire 115 may be made of a non-bioresorbable material chosen from among polypropylenes, polyesters such as polyethyleneterephthalates, polyamides, silicones, polyether ether ketone (PEEK), polyether ketone ketone (PEKK), polyarylether ether ketone (PAEK), polyurethanes and mixtures thereof. Additional support is therefore provided on a long term basis to the prosthesis 100 for holding the breast implant against gravity.

In another embodiment, said reinforcement member is formed by a combination of bioresorbable material and of non-bioresorbable material.

The wire 115 may be overmolded on the reinforcement part 101.

In embodiments, the reinforcement part 101 is linked to the transition part 103 by means of sewing, gluing, welding, overmolding and combinations thereof. In embodiments, the transition part 103 is linked to the fixation part 102 by means of sewing, gluing welding, overmolding and combinations thereof.

Alternatively, the first, second and third fabrics forming the reinforcement part, the transition part and the fixation part are made as a single unitary structure. For example, using a knitting machine and the proper knitting pattern and/or yarn, the whole prosthesis, namely the reinforcement part, fixation part and transition part, and more particularly the first, second and third fabrics may be knitted and formed as a single unitary structure requiring no sewing or cutting. Such embodiment allows a very natural appearance as significant thickness variations or fabric ridges are thereby avoided.

The reinforcement part 101 of FIGS. 3-9 comprises, or may consist in, a first fabric made of a first arrangement of yarns as described above in the present application, with in particular an elongation under 50N in the vertical direction referred to as E1. The fixation part 102 of FIGS. 3-9 comprises, or may consist in, a second fabric made of a second arrangement of yarns as described above in the present application, with in particular an elongation under 50N in the vertical direction referred to as E2. The transition part 103 of FIGS. 3-9 comprises, or may consist in, a third fabric made of a third arrangement of yarns as described above in the present application, with in particular an elongation under 50N in the vertical direction referred to as E3.

For each prosthesis 100 of FIGS. 3-9, the first, second and third fabrics are combined together so as to form the reinforcement part, the fixation part and the transition part, with the proviso that E3 is greater than E1 and greater than E2.

For example, for a prosthesis 100 of FIGS. 3-8, the reinforcement part 101 may be formed of Knit X described above, in combination with the fixation part 102 made of Knit F described above and with the transition part 103 made of Knit A described above. In such an embodiment, E1 is 25%, E2 is 5% and E3 is 50%.

In another example, for a prosthesis 100 of FIGS. 3-8, the reinforcement part 101 may be formed of Knit Y described above, in combination with the fixation part 102 made of Knit F described above and with the transition part 103 made of Knit B described above. In such an embodiment, E1 is 19%, E2 is 5% and E3 is 59%.

In another example, for a prosthesis 100 of FIGS. 3-8, the reinforcement part 101 may be formed of Knit Z described above, in combination with the fixation part 102 made of Knit F described above and with the transition part 103 made of Knit C described above. In such an embodiment, E1 is 35%, E2 is 5% and E3 is 46%.

With reference to FIG. 10 is shown a prosthesis 100 of FIGS. 3-9 in place within a patient in a view of supporting a breast implant 12. As shown on this Figure, the lower edge 104 of the reinforcement part 101 of the prosthesis 100 is sutured to the chest wall 8 by means of suture 200. Alternatively, the lower edge 104 of the reinforcement part 101 of the prosthesis 100 could be sutured to the infra-mammary fold 6. The reinforcement part 101 receives the lower curved portion of the breast implant 12 so as to cup said breast implant 12.

The fixation part 102 faces the pectoral muscle 7. In particular, in the surgical procedure shown, the implant breast 12 is positioned behind the pectoral muscle 7. The second fabric forming the fixation part 102 is provided with barbs 116 on its face fixed to the pectoral muscle 7.

With reference to FIG. 11 is shown another prosthesis 100 of the invention, comprising a reinforcement part 101, a fixation part 102 and a transition part 103. The fixation part 102 is provided with two arms 110. The prosthesis 100 is further provided with a recess 114 intended to face nipple-areola complex. In the prosthesis of FIG. 11, the recess 114 is located in the reinforcement part 101. Such a prosthesis is particularly adapted for lifting up healthy breast tissue in pure aesthetic surgery.

With reference to FIG. 12 is shown the prosthesis 100 of FIG. 11 in place within a patient in a view of supporting a healthy breast 1. No part of the healthy breast 1 has been removed and the lobules 4 and the milk ducts 5 are still present and received within the reinforcement part 101 of the prosthesis 100. As shown on this Figure, the lower edge 104 of the reinforcement part 101 of the prosthesis 100 is sutured to the chest wall 8 by means of suture 200. Alternatively, the lower edge 104 of the reinforcement part 101 of the prosthesis 100 could be sutured to the infra-mammary fold 6. The reinforcement part 101 receives the lower curved portion of the breast 1 so as to cup said breast 1.

The fixation part 102 faces the anterior face of the pectoral muscle 7. The second fabric forming the fixation part 102 is provided with barbs 116 on its face fixed to the anterior face of the pectoral muscle 7. The recess 114 is positioned facing the nipple-areola complex 2 so as to preserve it.

In order to implant the prosthesis 100 of the invention, the surgeon may perform the following steps:

a) making an incision in the area of the infra-mammary fold 6,

b) if needed, for example in breast reconstruction surgery, positioning the breast implant 12 between the chest wall 8 and the pectoral muscle 7,

c) positioning the prosthesis 100 so that the curve-shaped lower portion of the breast implant 12 or of the breast tissue is received in the reinforcement part 101, with the lower edge 104 of the reinforcement part 101 facing the chest wall 8, and an upper area of the fixation part 102 facing the pectoral muscle 7,

d) suturing the lower edge 104 of the reinforcement part 101 to the chest wall 8, for example by means of suture 200,

e) determining the best position of the fixation part 102 with respect to the pectoral muscle 8,

f) fixing the fixation part 102 to the pectoral muscle 7,

g) closing the incision.

For example, step e) may be completed by gripping and ungripping the fixation part 102, in particular the arms 110, as many times as necessary with the help of the barbs 116 present on the second fabric forming the fixation part 102. The barbs 116 may show a free end or head greater in width than a body of the barbs and a generally spheroidal or mushroom shape. The head of the barbs 116 are capable of penetrating in the pectoral muscle 7 for gripping each arm 110 to the pectoral muscle 7. The surgeon may examine whether the position of the arms 110 is correct or not. If the surgeon evaluates that the position should be corrected, he simply ungrips the arms 110 and proceeds to a second gripping of the arms 110 into the pectoral muscle 7. Thanks to the presence of the barbs 116, the fixation part 102 is repositionable. In addition, the determination of the adequate fixation position may be completed with the help of patient in a standing or seating position.

Because of its structure comprising at least three parts and because of the relative values of the respective elongations under 50N in the vertical direction of these three parts, the prosthesis of the invention once implanted in view of supporting a breast structure, allows for stretching and elasticity of the supported breast structure, in a manner very close to the natural behavior of a breast, thereby yielding a more natural appearance and movement during movement such as walking by the patient. The prosthesis of the invention further provides excellent support to the multi directional curves of the supported breast structure.

The structure of the prosthesis of the invention allows both efficient support to avoid sagging and bottoming out of the breast structure such as a breast implant and adequate elasticity for natural feel and movement. The prosthesis of the invention further supports the breast structure in the proper orientation.

Claims

1. A prosthesis for supporting a breast structure within a patient, the prosthesis comprising: a reinforcement part comprising a first fabric made of a first arrangement of yarns and configured to receive at least a curve-shaped lower portion of a breast structure, said reinforcement part intended to be sutured to a chest wall or to an infra-mammary fold, said first arrangement of yarns conferring to said first fabric an elongation under 50N in a vertical direction of E1,a fixation part comprising a second fabric made of a second arrangement of yarns and intended to be fixed to a pectoral muscle, said second arrangement of yarns conferring to said second fabric an elongation under 50N in a vertical direction of E2, anda transition part comprising a third fabric made of a third arrangement of yarns, said transition part connecting together said reinforcement part and said fixation part, said third arrangement of yarns conferring to said third fabric an elongation under 50N in a vertical direction of E3,wherein E3 is more than 50% greater than E1.
2. The prosthesis of claim 1, wherein E3 is more than 100% greater than E1.
3. The prosthesis of claim 1, wherein E3 is more than 200% greater than E1.
4. The prosthesis of claim 1, wherein E3 and E1 are greater than E2.
5. The prosthesis of claim 1, wherein said prosthesis includes a total height H and said transition part has a height h, measured along the vertical direction, wherein said prosthesis in a planar configuration includes an h/H ratio ranging from about 1/30 to about 1/2.
6. The prosthesis of claim 5, wherein said h/H ratio ranges from about 1/12 to about 1/4.
7. The prosthesis of claim 1, wherein said reinforcement part has a globally elongated shape in a horizontal direction, said shape showing a convex lower edge.
8. The prosthesis of claim 1, wherein said transition part has substantially a shape of a portion of a circular crown.
9. The prosthesis of claim 1, wherein said fixation part comprises a lower edge from which extends vertically and in an upper direction one or more arms intended to be fixed to the pectoral muscle.
10. The prosthesis of claim 9, wherein the one or more arms each include a lower end and an upper end, said lower end is substantially larger in a horizontal direction than said upper end.
11. The prosthesis of claim 1, wherein said first fabric is a three-dimensional porous knit.
12. The prosthesis of claim 11, wherein said second and third fabrics are each two-dimensional porous knits.
13. The prosthesis of claim 11, wherein said three-dimensional porous knit includes pores having a size above 1 mm×1 mm.
14. The prosthesis of claim 1, wherein said first fabric shows a bursting strength above about 400 kPa.
15. The prosthesis of claim 1, wherein a face of said first fabric intended to be in contact with the breast structure is covered with a low friction coating.
16. The prosthesis of claim 1, wherein a face of said second fabric intended to face the pectoral muscle is provided with barbs protruding from said face of said second fabric, said barbs capable of fixing at least temporarily said face of said second fabric to the pectoral muscle.
17. The prosthesis of claim 1, wherein said reinforcement part is provided with a reinforcement member configured for inducing a curved shape to said first fabric conformable with said curve-shaped lower portion of the breast structure.
18. The prosthesis of claim 1, wherein said first, second and third fabrics are made as a single unitary structure.
19. The prosthesis of claim 1, wherein the prosthesis includes a recess in the transition part.
20. A prosthesis for supporting a breast structure within a patient, the prosthesis comprising: a reinforcement part comprising a first fabric made of a first arrangement of yarns and configured to receive at least a curve-shaped lower portion of a breast structure, said reinforcement part intended to be sutured to a chest wall or to an infra-mammary fold, said first arrangement of yarns conferring to said first fabric an elongation under 50N in a vertical direction of E1,a fixation part comprising a second fabric made of a second arrangement of yarns and intended to be fixed to a pectoral muscle, said second arrangement of yarns conferring to said second fabric an elongation under 50N in a vertical direction of E2, anda transition part comprising a third fabric made of a third arrangement of yarns, said transition part connecting together said reinforcement part and said fixation part, said third arrangement of yarns conferring to said third fabric an elongation under 50N in a vertical direction of E3,wherein E3 is more than 100% greater than E2.

Priority Claims (1)

Number	Date	Country	Kind
15305634	Apr 2015	EP	regional

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 15/920,597 filed Mar. 14, 2018, which is a divisional of U.S. patent application Ser. No. 15/099,633 filed Apr. 15, 2016, now U.S. Pat. No. 9,931,198, which claims benefit of and priority to European Patent Application No. 153056354.6 filed Apr. 24, 2015, the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.

US Referenced Citations (495)

Number	Name	Date	Kind
1187158	Mcginley	Jun 1916	A
3054406	Usher	Sep 1962	A
3118294	Van Laethem	Jan 1964	A
3124136	Usher	Mar 1964	A
3272204	Artandi et al.	Sep 1966	A
3276448	Kronenthal	Oct 1966	A
3320649	Naimer	May 1967	A
3364200	Ashton et al.	Jan 1968	A
3570482	Shigeru et al.	Mar 1971	A
3718725	Hamano	Feb 1973	A
4006747	Kronenthal et al.	Feb 1977	A
4060081	Vannas et al.	Nov 1977	A
4173131	Melton et al.	Nov 1979	A
4193137	Heck	Mar 1980	A
4248064	Odham	Feb 1981	A
4294241	Miyata	Oct 1981	A
4307717	Hymes et al.	Dec 1981	A
4338800	Matsuda	Jul 1982	A
4476697	Schaefer	Oct 1984	A
4487865	Balazs et al.	Dec 1984	A
4500676	Balazs et al.	Feb 1985	A
4511653	Play et al.	Apr 1985	A
4527404	Nakagaki et al.	Jul 1985	A
4591501	Cioca	May 1986	A
4597762	Walter et al.	Jul 1986	A
4603695	Ikada et al.	Aug 1986	A
4631932	Sommers	Dec 1986	A
4670014	Huc et al.	Jun 1987	A
4709562	Matsuda	Dec 1987	A
4748078	Doi et al.	May 1988	A
4759354	Quarfoot	Jul 1988	A
4769038	Bendavid et al.	Sep 1988	A
4796603	Dahlke et al.	Jan 1989	A
4813942	Alvarez	Mar 1989	A
4840629	Bustos	Jun 1989	A
4841962	Berg et al.	Jun 1989	A
4854316	Davis	Aug 1989	A
4925294	Geshwind et al.	May 1990	A
4931546	Tardy et al.	Jun 1990	A
4942875	Hlavacek et al.	Jul 1990	A
4948540	Nigam	Aug 1990	A
4950483	Ksander et al.	Aug 1990	A
4970298	Silver et al.	Nov 1990	A
4976737	Leake	Dec 1990	A
5002551	Linsky et al.	Mar 1991	A
5015584	Brysk	May 1991	A
5071433	Naestoft et al.	Dec 1991	A
5116357	Eberbach	May 1992	A
5147374	Fernandez	Sep 1992	A
5162430	Rhee et al.	Nov 1992	A
5171273	Silver et al.	Dec 1992	A
5176692	Wilk et al.	Jan 1993	A
5192301	Kamiya et al.	Mar 1993	A
5195542	Gazielly et al.	Mar 1993	A
5196185	Silver et al.	Mar 1993	A
5201745	Tayot et al.	Apr 1993	A
5201764	Kelman et al.	Apr 1993	A
5206028	Li	Apr 1993	A
5217493	Raad et al.	Jun 1993	A
5254133	Seid	Oct 1993	A
5256418	Kemp et al.	Oct 1993	A
5258000	Gianturco	Nov 1993	A
5263983	Yoshizato et al.	Nov 1993	A
5304595	Rhee et al.	Apr 1994	A
5306500	Rhee et al.	Apr 1994	A
5324775	Rhee et al.	Jun 1994	A
5328955	Rhee et al.	Jul 1994	A
5334527	Brysk	Aug 1994	A
5339657	Mcmurray	Aug 1994	A
5350583	Yoshizato et al.	Sep 1994	A
5356432	Rutkow et al.	Oct 1994	A
5368549	Mcvicker	Nov 1994	A
5368602	Torre	Nov 1994	A
5370650	Jonathan et al.	Dec 1994	A
5376375	Rhee et al.	Dec 1994	A
5376376	Li	Dec 1994	A
5397331	Himpens et al.	Mar 1995	A
5399361	Song et al.	Mar 1995	A
5413791	Rhee et al.	May 1995	A
5425740	Hutchinson, Jr.	Jun 1995	A
5428022	Palefsky et al.	Jun 1995	A
5433996	Kranzler et al.	Jul 1995	A
5441491	Verschoor et al.	Aug 1995	A
5441508	Gazielly et al.	Aug 1995	A
5456693	Conston et al.	Oct 1995	A
5456711	Hudson	Oct 1995	A
5466462	Rosenthal et al.	Nov 1995	A
5480644	Freed	Jan 1996	A
5487895	Dapper et al.	Jan 1996	A
5490984	Freed	Feb 1996	A
5512291	Li	Apr 1996	A
5512301	Song et al.	Apr 1996	A
5514181	Light et al.	May 1996	A
5522840	Krajicek	Jun 1996	A
5523348	Rhee et al.	Jun 1996	A
5536656	Kemp et al.	Jul 1996	A
5543441	Rhee et al.	Aug 1996	A
5565210	Rosenthal et al.	Oct 1996	A
5567806	Abdul-Malak et al.	Oct 1996	A
5569273	Titone et al.	Oct 1996	A
RE35399	Eisenberg	Dec 1996	E
5584884	Pignataro	Dec 1996	A
5593441	Lichtenstein et al.	Jan 1997	A
5595621	Light et al.	Jan 1997	A
5601571	Moss	Feb 1997	A
5607474	Athanasiou et al.	Mar 1997	A
5607590	Shimizu	Mar 1997	A
5614587	Rhee et al.	Mar 1997	A
5618551	Tardy et al.	Apr 1997	A
5634931	Kugel	Jun 1997	A
5639796	Lee	Jun 1997	A
5665391	Lea	Sep 1997	A
5667839	Berg	Sep 1997	A
5676967	Williams et al.	Oct 1997	A
5681568	Goldin et al.	Oct 1997	A
5686090	Schilder et al.	Nov 1997	A
5686115	Vournakis et al.	Nov 1997	A
5690675	Sawyer et al.	Nov 1997	A
5695525	Mulhauser et al.	Dec 1997	A
5697978	Sgro	Dec 1997	A
5700476	Rosenthal et al.	Dec 1997	A
5700477	Rosenthal et al.	Dec 1997	A
5702416	Kieturakis et al.	Dec 1997	A
5709934	Bell et al.	Jan 1998	A
5711960	Shikinami	Jan 1998	A
5716409	Debbas	Feb 1998	A
5720981	Eisinger	Feb 1998	A
5732572	Litton	Mar 1998	A
5743917	Saxon	Apr 1998	A
5749895	Sawyer et al.	May 1998	A
5752974	Rhee et al.	May 1998	A
5766246	Mulhauser et al.	Jun 1998	A
5766631	Arnold	Jun 1998	A
5769864	Kugel	Jun 1998	A
5771716	Schlussel	Jun 1998	A
5785983	Furlan et al.	Jul 1998	A
5800541	Rhee et al.	Sep 1998	A
5814328	Gunasekaran	Sep 1998	A
5833705	Ken et al.	Nov 1998	A
5840011	Landgrebe et al.	Nov 1998	A
5861034	Taira et al.	Jan 1999	A
5863984	Doillon et al.	Jan 1999	A
5869080	Mcgregor et al.	Feb 1999	A
5871767	Dionne et al.	Feb 1999	A
5876444	Lai	Mar 1999	A
5891558	Bell et al.	Apr 1999	A
5899909	Claren et al.	May 1999	A
5906937	Sugiyama et al.	May 1999	A
5910149	Kuzmak	Jun 1999	A
5911731	Pham et al.	Jun 1999	A
5916225	Kugel	Jun 1999	A
5919232	Chaffringeon et al.	Jul 1999	A
5919233	Knopf et al.	Jul 1999	A
5922026	Chin	Jul 1999	A
5931165	Reich et al.	Aug 1999	A
5942278	Hagedorn et al.	Aug 1999	A
5962136	Dewez et al.	Oct 1999	A
5972022	Huxel	Oct 1999	A
RE36370	Li	Nov 1999	E
5993844	Abraham et al.	Nov 1999	A
5994325	Roufa et al.	Nov 1999	A
5997895	Narotam et al.	Dec 1999	A
6001895	Harvey et al.	Dec 1999	A
6008292	Lee et al.	Dec 1999	A
6015844	Harvey et al.	Jan 2000	A
6039686	Robert	Mar 2000	A
6042534	Gellman et al.	Mar 2000	A
6042592	Schmitt	Mar 2000	A
6043089	Sugiyama et al.	Mar 2000	A
6051425	Morota et al.	Apr 2000	A
6056688	Benderev et al.	May 2000	A
6056970	Greenawalt et al.	May 2000	A
6057148	Sugiyama et al.	May 2000	A
6063396	Kelleher	May 2000	A
6066776	Goodwin et al.	May 2000	A
6066777	Benchetrit	May 2000	A
6071292	Makower et al.	Jun 2000	A
6077281	Das	Jun 2000	A
6080194	Pachence et al.	Jun 2000	A
6083522	Chu et al.	Jul 2000	A
6090116	D Aversa et al.	Jul 2000	A
6113623	Sgro	Sep 2000	A
6120539	Eldridge et al.	Sep 2000	A
6132765	Dicosmo et al.	Oct 2000	A
6143037	Goldstein et al.	Nov 2000	A
6153292	Bell et al.	Nov 2000	A
6162962	Hinsch et al.	Dec 2000	A
6165488	Tardy et al.	Dec 2000	A
6171318	Kugel et al.	Jan 2001	B1
6174320	Kugel et al.	Jan 2001	B1
6176863	Kugel et al.	Jan 2001	B1
6179872	Bell et al.	Jan 2001	B1
6180848	Flament et al.	Jan 2001	B1
6197325	Macphee et al.	Mar 2001	B1
6197934	Devore et al.	Mar 2001	B1
6197935	Doillon et al.	Mar 2001	B1
6210439	Firmin et al.	Apr 2001	B1
6214020	Mulhauser et al.	Apr 2001	B1
6221109	Geistlich et al.	Apr 2001	B1
6224616	Kugel	May 2001	B1
6241768	Agarwal et al.	Jun 2001	B1
6258124	Darois et al.	Jul 2001	B1
6262332	Ketharanathan	Jul 2001	B1
6264702	Ory et al.	Jul 2001	B1
6267772	Mulhauser et al.	Jul 2001	B1
6270530	Eldridge et al.	Aug 2001	B1
6277397	Shimizu	Aug 2001	B1
6280453	Kugel et al.	Aug 2001	B1
6287316	Agarwal et al.	Sep 2001	B1
6290708	Kugel et al.	Sep 2001	B1
6306079	Trabucco	Oct 2001	B1
6306424	Vyakarnam et al.	Oct 2001	B1
6312474	Francis et al.	Nov 2001	B1
6319264	Tormala et al.	Nov 2001	B1
6328686	Robert	Dec 2001	B1
6334872	Termin et al.	Jan 2002	B1
6383201	Dong	May 2002	B1
6391060	Ory et al.	May 2002	B1
6391333	Li et al.	May 2002	B1
6391939	Tayot et al.	May 2002	B2
6408656	Ory et al.	Jun 2002	B1
6410044	Chudzik et al.	Jun 2002	B1
6413742	Olsen et al.	Jul 2002	B1
6425924	Rousseau	Jul 2002	B1
6428978	Olsen et al.	Aug 2002	B1
6436030	Rehil	Aug 2002	B2
6440167	Shimizu	Aug 2002	B2
6443964	Ory et al.	Sep 2002	B1
6447551	Goldmann	Sep 2002	B1
6447802	Sessions et al.	Sep 2002	B2
6448378	Devore et al.	Sep 2002	B2
6451032	Ory et al.	Sep 2002	B1
6451301	Sessions et al.	Sep 2002	B1
6454787	Maddalo et al.	Sep 2002	B1
6477865	Matsumoto	Nov 2002	B1
6479072	Morgan et al.	Nov 2002	B1
6485503	Jacobs et al.	Nov 2002	B2
6500464	Ceres et al.	Dec 2002	B2
6500777	Wiseman et al.	Dec 2002	B1
6509031	Miller et al.	Jan 2003	B1
6511958	Atkinson et al.	Jan 2003	B1
6514286	Leatherbury et al.	Feb 2003	B1
6514514	Atkinson et al.	Feb 2003	B1
6540773	Dong	Apr 2003	B2
6541023	Andre et al.	Apr 2003	B1
6548077	Gunasekaran	Apr 2003	B1
6554855	Dong	Apr 2003	B1
6559119	Burgess et al.	May 2003	B1
6566345	Miller et al.	May 2003	B2
6575988	Rousseau	Jun 2003	B2
6576019	Atala	Jun 2003	B1
6596002	Therin et al.	Jul 2003	B2
6596304	Bayon et al.	Jul 2003	B1
6599323	Melican et al.	Jul 2003	B2
6599524	Li et al.	Jul 2003	B2
6599690	Abraham et al.	Jul 2003	B1
6610006	Amid et al.	Aug 2003	B1
6613348	Jain	Sep 2003	B1
6616685	Rousseau	Sep 2003	B2
6623963	Mueller et al.	Sep 2003	B1
6630414	Matsumoto	Oct 2003	B1
6637437	Hungerford et al.	Oct 2003	B1
6638284	Rousseau et al.	Oct 2003	B1
6645226	Jacobs et al.	Nov 2003	B1
6652594	Francis et al.	Nov 2003	B2
6652595	Nicolo	Nov 2003	B1
6653450	Berg et al.	Nov 2003	B1
6656206	Corcoran et al.	Dec 2003	B2
6660280	Allard et al.	Dec 2003	B1
6666893	Burg	Dec 2003	B2
6669735	Pelissier	Dec 2003	B1
6670018	Fujita et al.	Dec 2003	B2
6682760	Noff et al.	Jan 2004	B2
6685714	Rousseau	Feb 2004	B2
6706684	Bayon et al.	Mar 2004	B1
6706690	Reich et al.	Mar 2004	B2
6712859	Rousseau et al.	Mar 2004	B2
6719795	Bryan et al.	Apr 2004	B1
6723335	Moehlenbruck et al.	Apr 2004	B1
6726660	Hessel et al.	Apr 2004	B2
6730299	Tayot et al.	May 2004	B1
6736823	Darois et al.	May 2004	B2
6736854	Vadurro et al.	May 2004	B2
6737371	Planck et al.	May 2004	B1
6743435	Devore et al.	Jun 2004	B2
6746458	Cloud	Jun 2004	B1
6752834	Geistlich et al.	Jun 2004	B2
6755868	Rousseau	Jun 2004	B2
6773723	Spiro et al.	Aug 2004	B1
6783554	Amara et al.	Aug 2004	B2
6790213	Cherok et al.	Sep 2004	B2
6790454	Abdul et al.	Sep 2004	B1
6800082	Rousseau	Oct 2004	B2
6833408	Sehl et al.	Dec 2004	B2
6835336	Watt	Dec 2004	B2
6852330	Bowman et al.	Feb 2005	B2
6869938	Schwartz et al.	Mar 2005	B1
6872227	Sump et al.	Mar 2005	B2
6893653	Abraham et al.	May 2005	B2
6896904	Spiro et al.	May 2005	B2
6926723	Mulhauser et al.	Aug 2005	B1
6936276	Spiro et al.	Aug 2005	B2
6939562	Spiro et al.	Sep 2005	B2
6949625	Tayot	Sep 2005	B2
6966918	Schuldt-Hempe et al.	Nov 2005	B1
6971252	Therin et al.	Dec 2005	B2
6974679	Andre et al.	Dec 2005	B2
6974862	Ringeisen et al.	Dec 2005	B2
6977231	Matsuda	Dec 2005	B1
6984392	Bechert et al.	Jan 2006	B2
6988386	Okawa et al.	Jan 2006	B1
7011688	Gryska et al.	Mar 2006	B2
7021086	Ory et al.	Apr 2006	B2
7022358	Eckmayer et al.	Apr 2006	B2
7025063	Snitkin et al.	Apr 2006	B2
7041868	Greene et al.	May 2006	B2
7060103	Carr et al.	Jun 2006	B2
RE39172	Bayon et al.	Jul 2006	E
7070558	Gellman et al.	Jul 2006	B2
7087065	Ulmsten et al.	Aug 2006	B2
7094261	Zotti et al.	Aug 2006	B2
7098315	Schaufler	Aug 2006	B2
7101381	Ford et al.	Sep 2006	B2
7115220	Dubson et al.	Oct 2006	B2
7156804	Nicolo	Jan 2007	B2
7156858	Schuldt-Hempe et al.	Jan 2007	B2
7175852	Simmoteit et al.	Feb 2007	B2
7192604	Brown et al.	Mar 2007	B2
7207962	Anand et al.	Apr 2007	B2
7214765	Ringeisen et al.	May 2007	B2
7226611	Yura et al.	Jun 2007	B2
7229453	Anderson et al.	Jun 2007	B2
7252837	Guo et al.	Aug 2007	B2
7279177	Looney et al.	Oct 2007	B2
7331199	Dry et al.	Feb 2008	B2
7393319	Merade et al.	Jul 2008	B2
7476249	Frank	Jan 2009	B2
7556598	Rao	Jul 2009	B2
7594921	Browning	Sep 2009	B2
7614258	Cherok et al.	Nov 2009	B2
7615065	Priewe et al.	Nov 2009	B2
7662169	Wittmann	Feb 2010	B2
7670372	Shfaram et al.	Mar 2010	B2
7670380	Cauthen, III et al.	Mar 2010	B2
7682381	Rakos et al.	Mar 2010	B2
7709017	Tayot et al.	May 2010	B2
7718556	Matsuda et al.	May 2010	B2
7732354	Fricke et al.	Jun 2010	B2
7785334	Ford et al.	Aug 2010	B2
7789888	Bartee et al.	Sep 2010	B2
7799767	Lamberti et al.	Sep 2010	B2
7806905	Ford et al.	Oct 2010	B2
7824420	Eldridge et al.	Nov 2010	B2
7828854	Rousseau et al.	Nov 2010	B2
7875074	Chen	Jan 2011	B2
7900484	Cherok et al.	Mar 2011	B2
7931695	Ringeisen	Apr 2011	B2
7998152	Frank	Aug 2011	B2
8007531	Frank	Aug 2011	B2
8052759	Dupic et al.	Nov 2011	B2
8079023	Chen	Dec 2011	B2
8100924	Browning	Jan 2012	B2
8123817	Intoccia et al.	Feb 2012	B2
8142515	Therin et al.	Mar 2012	B2
8157821	Browning	Apr 2012	B2
8157822	Browning	Apr 2012	B2
8182545	Cherok et al.	May 2012	B2
8197837	Jamiolkowski et al.	Jun 2012	B2
8206632	Rousseau et al.	Jun 2012	B2
8215310	Browning	Jul 2012	B2
8317872	Adams	Nov 2012	B2
8323675	Greenawalt	Dec 2012	B2
8343232	Adzich et al.	Jan 2013	B2
8366787	Brown et al.	Feb 2013	B2
8435307	Paul	May 2013	B2
8470355	Skalla et al.	Jun 2013	B2
8506627	Van et al.	Aug 2013	B2
8562633	Cully et al.	Oct 2013	B2
8574627	Martakos et al.	Nov 2013	B2
8709094	Stad et al.	Apr 2014	B2
8728159	Kim et al.	May 2014	B2
8734471	Deitch	May 2014	B2
8746014	Mortarino	Jun 2014	B2
8753360	Gleiman et al.	Jun 2014	B2
8758800	Stopek et al.	Jun 2014	B2
8784294	Goddard	Jul 2014	B2
8814887	Walther et al.	Aug 2014	B2
8828092	Toso et al.	Sep 2014	B2
8834864	Odar et al.	Sep 2014	B2
8846060	Archibald et al.	Sep 2014	B2
8865215	Ladet et al.	Oct 2014	B2
8877233	Obermiller et al.	Nov 2014	B2
8911504	Mathisen et al.	Dec 2014	B2
8920370	Sholev et al.	Dec 2014	B2
8956373	Ford et al.	Feb 2015	B2
8962006	Bayon et al.	Feb 2015	B2
8968762	Ladet et al.	Mar 2015	B2
8979935	Lozier et al.	Mar 2015	B2
9034357	Stopek	May 2015	B2
9113993	Lee	Aug 2015	B2
9211175	Stopek et al.	Dec 2015	B2
9216075	Bailly et al.	Dec 2015	B2
9931198	Doucet	Apr 2018	B2
10398542	Griffin	Sep 2019	B2
10660741	Doucet	May 2020	B2
20020087174	Capello	Jul 2002	A1
20020095218	Carr et al.	Jul 2002	A1
20030086975	Ringeisen	May 2003	A1
20030106346	Matsumoto	Jun 2003	A1
20030114937	Leatherbury et al.	Jun 2003	A1
20030133967	Ruszczak et al.	Jul 2003	A1
20030225355	Butler	Dec 2003	A1
20040034373	Schuldt-Hempe et al.	Feb 2004	A1
20040054376	Ory et al.	Mar 2004	A1
20040059356	Gingras	Mar 2004	A1
20040101546	Gorman et al.	May 2004	A1
20050002893	Goldmann	Jan 2005	A1
20050021058	Negro	Jan 2005	A1
20050085924	Darois et al.	Apr 2005	A1
20050113849	Popadiuk et al.	May 2005	A1
20050137512	Campbell et al.	Jun 2005	A1
20050142161	Freeman et al.	Jun 2005	A1
20050148963	Brennan	Jul 2005	A1
20050175659	Macomber et al.	Aug 2005	A1
20050232979	Shoshan	Oct 2005	A1
20050267521	Forsberg	Dec 2005	A1
20050288691	Leiboff	Dec 2005	A1
20060036266	Sulamanidze et al.	Feb 2006	A1
20060116696	Odermatt et al.	Jun 2006	A1
20060135921	Wiercinski et al.	Jun 2006	A1
20060147501	Hillas et al.	Jul 2006	A1
20060216320	Kitazono et al.	Sep 2006	A1
20060252981	Matsuda et al.	Nov 2006	A1
20060253203	Alvarado	Nov 2006	A1
20060282103	Fricke et al.	Dec 2006	A1
20070088391	Mcalexander et al.	Apr 2007	A1
20070129736	Solecki	Jun 2007	A1
20070198040	Buevich et al.	Aug 2007	A1
20070299538	Roeber	Dec 2007	A1
20080091276	Deusch et al.	Apr 2008	A1
20080109017	Herweck et al.	May 2008	A1
20080113001	Herweck et al.	May 2008	A1
20080172071	Barker	Jul 2008	A1
20080255593	St-Germain	Oct 2008	A1
20090035341	Wagener et al.	Feb 2009	A1
20090036996	Roeber	Feb 2009	A1
20090068250	Gravagna et al.	Mar 2009	A1
20090105526	Piroli et al.	Apr 2009	A1
20090163936	Yang et al.	Jun 2009	A1
20090187197	Roeber et al.	Jul 2009	A1
20090192530	Adzich et al.	Jul 2009	A1
20090204129	Fronio	Aug 2009	A1
20090216338	Gingras et al.	Aug 2009	A1
20090270999	Brown	Oct 2009	A1
20090281558	Li et al.	Nov 2009	A1
20090318752	Evans et al.	Dec 2009	A1
20100104608	Abuzaina et al.	Apr 2010	A1
20100137679	Lashinski et al.	Jun 2010	A1
20100318108	Datta et al.	Dec 2010	A1
20110015760	Kullas	Jan 2011	A1
20110054604	Becker	Mar 2011	A1
20110144667	Horton et al.	Jun 2011	A1
20110190795	Hotter et al.	Aug 2011	A1
20110238094	Thomas et al.	Sep 2011	A1
20110251699	Ladet et al.	Oct 2011	A1
20110257666	Ladet et al.	Oct 2011	A1
20110257761	Mortarino	Oct 2011	A1
20120004723	Mortarino et al.	Jan 2012	A1
20120016388	Houard et al.	Jan 2012	A1
20120029537	Mortarino	Feb 2012	A1
20120053690	Frank	Mar 2012	A1
20120065727	Reneker et al.	Mar 2012	A1
20120082712	Stopek et al.	Apr 2012	A1
20120116425	Intoccia et al.	May 2012	A1
20120150204	Mortarino et al.	Jun 2012	A1
20120165937	Montanari et al.	Jun 2012	A1
20120179175	Hammell et al.	Jul 2012	A1
20120179176	Wilson et al.	Jul 2012	A1
20120197415	Montanari et al.	Aug 2012	A1
20120226352	Becker	Sep 2012	A1
20120283826	Moses et al.	Nov 2012	A1
20130253645	Kerr et al.	Sep 2013	A1
20140044861	Boey et al.	Feb 2014	A1
20140100656	Namnoum et al.	Apr 2014	A1
20140222161	Mathisen	Aug 2014	A1
20140276993	Reilly et al.	Sep 2014	A1
20140364684	Lecuivre et al.	Dec 2014	A1
20150250574	Egnelov	Sep 2015	A1
20150351899	Mortarino	Dec 2015	A1
20160193026	Mortarino	Jul 2016	A1
20160213456	Mortarino	Jul 2016	A1
20160213457	Mortarino	Jul 2016	A1
20160242899	Lee	Aug 2016	A1
20170027678	Greenhalgh	Feb 2017	A1
20170216009	Felix	Aug 2017	A1

Foreign Referenced Citations (140)

Number	Date	Country
1317836	May 1993	CA
201879864	Jun 2011	CN
19544162	Apr 1997	DE
19718903	Dec 1997	DE
19751733	Dec 1998	DE
19832634	Jan 2000	DE
10019604	Oct 2001	DE
10120942	Oct 2001	DE
10043396	Jun 2002	DE
0194192	Sep 1986	EP
0248544	Dec 1987	EP
0263360	Apr 1988	EP
0276890	Aug 1988	EP
0372969	Jun 1990	EP
0531742	Mar 1993	EP
0544485	Jun 1993	EP
0552576	Jul 1993	EP
0611561	Aug 1994	EP
0614650	Sep 1994	EP
0621014	Oct 1994	EP
0625891	Nov 1994	EP
0637452	Feb 1995	EP
0664132	Jul 1995	EP
0705878	Apr 1996	EP
0719527	Jul 1996	EP
0774240	May 1997	EP
0797962	Oct 1997	EP
0800791	Oct 1997	EP
0827724	Mar 1998	EP
0836838	Apr 1998	EP
0847727	Jun 1998	EP
0876808	Nov 1998	EP
0895762	Feb 1999	EP
0898944	Mar 1999	EP
1017415	Jul 2000	EP
1036545	Sep 2000	EP
1052319	Nov 2000	EP
1055757	Nov 2000	EP
1090590	Apr 2001	EP
1216717	Jun 2002	EP
1216718	Jun 2002	EP
0693523	Nov 2002	EP
1273312	Jan 2003	EP
1315468	Jun 2003	EP
1382728	Jan 2004	EP
1484070	Dec 2004	EP
1561480	Aug 2005	EP
1645232	Apr 2006	EP
1674048	Jun 2006	EP
1691606	Aug 2006	EP
1782848	May 2007	EP
2229918	Sep 2010	EP
2244853	Apr 1975	FR
2257262	Aug 1975	FR
2308349	Nov 1976	FR
2453231	Oct 1980	FR
2612392	Sep 1988	FR
2682284	Apr 1993	FR
2715309	Jul 1995	FR
2715405	Jul 1995	FR
2724563	Mar 1996	FR
2730406	Aug 1996	FR
2744906	Aug 1997	FR
2766698	Feb 1999	FR
2771622	Jun 1999	FR
2773057	Jul 1999	FR
2774277	Aug 1999	FR
2779937	Dec 1999	FR
2859624	Dec 2005	FR
2876020	Apr 2006	FR
2863277	Jun 2006	FR
2884706	Apr 2008	FR
2929834	Oct 2009	FR
2953709	Jun 2011	FR
1174814	Dec 1969	GB
2051153	Jan 1981	GB
2306110	Apr 1997	GB
H0332677	Mar 1991	JP
05237128	Sep 1993	JP
H09137380	May 1997	JP
H11146888	Jun 1999	JP
2008538300	Oct 2008	JP
2011078767	Apr 2011	JP
563828	Sep 2011	NZ
8902445	Mar 1989	WO
8908467	Sep 1989	WO
9012551	Nov 1990	WO
9206639	Apr 1992	WO
9220349	Nov 1992	WO
9310731	Jun 1993	WO
9311805	Jun 1993	WO
9318174	Sep 1993	WO
9417747	Aug 1994	WO
9507666	Mar 1995	WO
9518638	Jul 1995	WO
9532687	Dec 1995	WO
9603091	Feb 1996	WO
9608277	Mar 1996	WO
9609795	Apr 1996	WO
9614805	May 1996	WO
9641588	Dec 1996	WO
9735533	Oct 1997	WO
9835632	Aug 1998	WO
9849967	Nov 1998	WO
9905990	Feb 1999	WO
9906079	Feb 1999	WO
9906080	Feb 1999	WO
9951163	Oct 1999	WO
0016821	Mar 2000	WO
0067663	Nov 2000	WO
0115625	Mar 2001	WO
0180773	Nov 2001	WO
0181667	Nov 2001	WO
0207648	Jan 2002	WO
0217853	Mar 2002	WO
02078568	Oct 2002	WO
03002168	Jan 2003	WO
2004004600	Jan 2004	WO
2004071349	Aug 2004	WO
2004078120	Sep 2004	WO
2004096098	Nov 2004	WO
2004103212	Dec 2004	WO
2005011280	Feb 2005	WO
2005013863	Feb 2005	WO
2005018698	Mar 2005	WO
2005048708	Jun 2005	WO
2005105172	Nov 2005	WO
2006018552	Feb 2006	WO
2006023414	Mar 2006	WO
2007004214	Jan 2007	WO
2008066883	Jun 2008	WO
2009039373	Mar 2009	WO
2009071998	Jun 2009	WO
2009031035	Jan 2010	WO
2010043978	Apr 2010	WO
2007048099	Sep 2010	WO
2011007062	Jan 2011	WO
2011026987	Mar 2011	WO
2011038740	Apr 2011	WO
2014041577	Mar 2014	WO

Non-Patent Literature Citations (33)

Entry
Amid, P., “Lichtenstein tension-free hernioplasty: Its inception, evolution, and principles,” Hernia, 2004; pp. 1-7, 8, published online Sep. 2003.
Blondin, C. et al., “Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) from Brown Seaweed,” Molecular Immuol., Mar. 1994, pp. 247-253, 31(4).
Blondin, C. et al., “Relationships between chemical characteristics and anticomplementary activity of fucans,” Biomatenals, Mar. 1996, pp. 597-603, 17(6).
Boisson-Vidal, C. et al., “Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan From Marine Algae,” Cardiovascular & Hematological Agents in Medicinal Chem., Jan. 2007, pp. 67-77, 5(1).
Bracco, P. et al., “Comparison of polypropylene and polyethylene terephthalate (Dacron) meshes for abdominal wall hernia repair: A chemical and morphological study,” Hernia, 2005, pp. 51-55, 9 (1), published online Sep. 2004.
Chen, G. et al., “A Hybrid Network of Synthetic Polymer Mesh and Collagen Sponge,” The Royal Society of Chemistry 2000, Chem. Commun., Jul. 2000, pp. 1505-1506.
Collins, R. et al., “Use of collagen film as a dural substitute: Preliminary animal studies,” Journal of Biomedical Materials Research, Feb. 1991, pp. 267-276, vol. 25.
Communication pursuant to Article 94(3) EPC issued in European Patent Application No. 15305634.3 dated Nov. 13, 2019, 5 pages.
Dr. S. Raz, “The Karl Mayer Guide to Tehnical Textiles,” Jan. 2000, pp. 1-36, Obertshausen, Germany.
European Search Report for EP 15305634.6 date of completion is Nov. 2, 2015 (3 pages).
Examination report No. 1 for standard patent application issued in Australian Application No. 2016201622 dated Mar. 3, 2020, 3 pages.
Haneji, K. et al., “Fucoidan extracted from Cladosiphon Okamuranus Tokida Induces Apoptosis of Human T-cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells,” Nutrition and Cancer, 2005, 7 pp. 189-201, 52(2), published online Nov. 2009.
Haroun-Bouhedja, F. et al., “In Vitro Effects of Fucans on MDA-MB231 Tumor Cell Adhesion and Invasion,” Anticancer Res., Jul.-Aug. 2002, pp. 2285-2292, 22(4).
Haroun-Bouhedja, F. et al., “Relationship between sulfate groups and biological activities of fucans,” Thrombosis Res., Dec. 2000, pp. 453-459, 100(5).
Hirano, S. et al., “The blood biocompatibility of chitosan and N-acylchitosans,” J. Biomed. Mater. Res., Apr. 1985, 413-417, 19.
Junge, K. et al., “Functional and Morphologic Properties of a Modified Mesh for Inguinal Hernia Repair,” World J. Surg., Sep. 2002, pp. 1472-1480, 26.
Kanabar, V. et al., “Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle,” Br. J. Pharmacol., Oct. 2005, pp. 370-777, 146(3).
Klinge, U. et al., “Foreign Body Reaction to Meshes Used for the Repair of Abdominal Wall Hernias,” Eur J. Surg, Sep. 1999, pp. 665-673, 165.
Klinge, U. et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair,” J. Biomed. Mater. Res., Jan. 2002, pp. 129-136, 63.
Langenbech, M. R. et al., “Comparison of biomaterials in the early postoperative period,” Surg Endosc., May 2003, pp. 1105-1109, 17 (7).
Logeart, D. et al., “Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect,” Eur. J. Cell. Biol., Dec. 1997, pp. 385-390, 74(4).
Malette, W. G. et al., “Chitosan, A New Hemostatic,” Ann Th. Surg., Jul. 1983, pp. 55-58, 36.
Muzzarelli, R. et al., “Reconstruction of parodontal tissue with chitosan,” Biomaterials, Nov. 1989, pp. 598-604, 10.
O'Dwyer, P. et al., “Randomized clinical trial assessing impact of a lightweight or heavyweight mesh on chronic pain after inguinal hernia repair,” Br. J. Surg., Feb. 2005, pp. 166-170, 92(2).
Prokop, A. et al., “Water Soluble Polymers for Immunoisolation I: Complex Coacevation and Cytotoxicity,” Advances in Polymer Science, Jul. 1998, pp. 1-51, 136.
Rao, B. et al., “Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential,” J. Biomed. Mater. Res., Jan. 1997, pp. 21-28, 34.
Rosen, M. et al., “Laparoscopic component separation in the single-stage treatment of infected abdominal wall prosthetic removal,” Hernia, 2007, pp. 435-440, 11, published online Jul. 2007.
Scheidbach, H. et al., “In vivo studies comparing the biocompatibility of various polypropylene meshes and their handling properties during endoscopic total extraperitoneal (TEP) patchplasty: An experimental study in pigs,” Surg. Endosc., Feb. 2004, pp. 211-220, 18(2).
Strand, S. et al., “Screening of Chitosans and Conditions for Bacterial Flocculation,” Biomacromolecules, Mar. 2001, 126-133, 2.
Varum, K. et al., “In vitro degradation rates of partially N-acetylated chitosans in human serum,” Carbohydrate Research, Mar. 1997, pp. 99-101, 299.
Welty, G. et al., “Functional impairment and complaints following incisional hernia repair with different polypropylene meshes,” Hernia, Aug. 2001; pp. 142-147, 5.
Zvyagintseva, T. et al., “Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds,” Comparative Biochem and Physiol, Jul. 2000, pp. 209-215, 126(3).
Examination report No. 2 issued in Australian Patent Application No. 2016201622 dated Aug. 21, 2020, 4 pages.

Related Publications (1)

	Number	Date	Country
	20200237500 A1	Jul 2020	US

Divisions (2)

	Number	Date	Country
Parent	15920597	Mar 2018	US
Child	16850063		US
Parent	15099633	Apr 2016	US
Child	15920597		US

Prosthesis for supporting a breast structure

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Disclaimer

Term Extension

Abstract

Description

Claims

Priority Claims (1)

CROSS-REFERENCE TO RELATED APPLICATIONS

US Referenced Citations (495)

Foreign Referenced Citations (140)

Non-Patent Literature Citations (33)

Related Publications (1)

Divisions (2)